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General introduction
1.1 The rationale for the research
Bony defects in the maxillofacial area can be the result of trauma, cancer, infections or
other bone diseases and congenital malformations. These defects result in either functional
or esthetic problems. In maxillofacial reconstructive surgery, it is aimed to restore these
defects. The use of autogenous bone is still considered to be the gold standard5.
Interest in the transplantation of bone for skeletal reconstruction goes back to the 17th cen-
tury. The ﬁrst bone graft procedure was described in 1668 by the Dutch surgeon Job van
Meekeren who successfully repaired a traumatic defect in a soldier’s cranium by the use of
a dog’s skull3. Since then, several experiments have been described, using nonvascularized
auto- and allografts17. In the beginning, these grafts were ﬁxed by wire osteosynthesis and
intermaxillary ﬁxation. The disadvantage of a long postoperative period of intermaxilary
ﬁxation was overcome with the introduction of orthopedic compression plates, which were
applied since 197510. These plates could also be used to bridge the resected bone segments
itself, but fractures because of metal fatigue were an important disadvantage of this tech-
nique. Large reconstruction plates, however, are still widely used when a more extensive
reconstruction is needed. Other drawbacks of large plates are the fact that they are bulky
and thus palpable or visible under the skin, as well as causing bone resorption due to the
stress shielding eﬀect. In 1994, a new technique was therefore introduced: making use of
miniplates that were ﬁxed by screws13. Another technique that gained popularity was the
use of a scaﬀold, made of titanium mesh or polymer tray, which could be ﬁlled with au-
togenous particulate cancellous bone for anatomically reconstruction. These scaﬀolds were
diﬃcult to remove and sometimes resulted in infections and stress shielding. The place-
ment of oral implants could be hampered also by the remaining scaﬀold. Approximately
40 years ago, the ﬁrst vascularized grafts were used by means of a surgical anastomosis of
a nutrient vascular pedicle from the donor to the recipient site. Only autografts can be
used for these microvascular reconstructions. This implied a major step forward in the ar-
mamentarium of the reconstructive surgeon and greatly improved the quality and reliability
of the reconstructions in the maxillofacial area. The main disadvantage of this technique,
however, is the considerable morbidity associated with the harvesting of the donor bone.
The above mentioned brief overview of the history of bony reconstructions emphasizes the
need for alternatives that are both less harming to the patient and yet providing a suitable
reconstruction.
1.2 Terminology
The main reason to use autogenous bone for reconstructive purposes is the fact that these
grafts are osteogenic, osteoinductive and osteoconductive and immunological compatible.
The osteogenic potential is provided by bone forming cells present in bone marrow, which
are directly delivered at the recipient site. Osteoinductivity means the capacity to recruit
mesenchymal cells and induce them to diﬀerentiate into osteogenic cells through the expo-
sure of osteoinductive growth factors. The term osteoconductivity refers to the ability of
forming a three-dimensional structure, mainly composed of hydroxylapatite and collagen,
to allow for the inﬁltration of osteogenic cells1. There are, however, several drawbacks
when using autogenous bone, such as donor site morbidity, extended surgical time, costs
and limited availability. These drawbacks are the reason for a general interest in the use
of bone substitutes. For this purpose, several materials have already been used, such as
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allografts, xenografts and synthetic bone substitutes4. Allografting is the transplantation
of bone from a donor to a recipient of the same species. Allografts are less osteogenic
and more immunogenic, they also show a greater tendency to be resorbed and can cause
the transmission of diseases. Xenografting is the transplantation of bone from a donor
to a recipient of a diﬀerent species and carries an even greater risk of immune rejection4.
Synthetic bone substitutes can be divided into polymers, calciumphosphates and bioactive
glass. The advantages of these synthetic materials are their unlimited availability and non-
immunogenicity12. The ideal bone substitute would mimic the ostegenetic capacity of bone.
The substitutes currently available, can be used to improve the healing of bone defects, but
they do not possess osteogenic properties. Another drawback is the fact that most of these
substitutes are not completely biodegradable.
1.3 Bone
Bone is a natural composite material, roughly consisting of 60% of mineral, 30% of organic
matrix and 10% of water19. Bone is an organ with a supporting and protecting function
in the human body. It is also responsible for calcium homeostasis and hematopoiesis. It
is a very dynamic tissue, in that it is remodelled constantly by bone resorption and bone
deposition in the same location. The mineral part consists of calcium phosphates and its
major component is hydroxylapatite (Ca10(PO4)6(OH)2). The organic part is composed of
bone cells and an extracellular matrix, i.e. a network of proteins, from which collagen type I is
the main component (95%). The remaining 5% presents proteoglycans and non-collagenous
proteins. Bone cells originate from mesenchymal stem cells which can diﬀerentiate into so
called osteoprogenitor cells, eventually forming osteoblasts. The mature osteoblast will
become a bone forming cell or diﬀerentiate into an osteoclast. In bone remodelling, three
types of bone cells are active, i.e. osteoblasts, osteocytes and osteoclasts. Osteoblasts
are mononucleate cells, responsible for the formation and mineralisation of osteoid, which
mainly consists of type I collagen. When osteoblasts become trapped in the matrix they
secrete, they become osteocytes (Figure 1.1A). Osteoclasts are multinucleated giant cells,
responsible for the reorption of mineralized matrix6. Based on the structure, bone can be
divided into diﬀerent types of bone, i.e. trabecular or cancellous and cortical or compact
bone. Cortical bone is more dense and plays an important role in the mechanical support
and is found as outer shell of bones. Trabecular bone is less dense and is metabolically
more active and is found in the centre of bones11 (Figure 1.1B). The formation of bone can
occur by two diﬀerent processes. In the intramembranous process, mesenchymal progenitor
cells diﬀerentiate into osteoblasts, bone matrix is formed and mineralized afterwards. In
the enchondral process, a cartilaginous tissue is formed at ﬁrst, which will be replaced by
bone afterwards. Intramembraneous ossiﬁcation is mainly found in the development of ﬂat
bones, such as the skull, clavicula and parts of the mandible. The long bones are formed
by enchondral ossiﬁcation and the same occurs in fracture healing.
1.4 Bone healing
The same cells and signalling molecules, as present in embryologic bone formation, play a
role in bone healing and takes place in four stages. The process of healing starts with an
inﬂammatory response, incited by injury. The damage to blood vessels causes extravasation,
resulting in the formation of a hematoma. Platelets within the hematoma control hemostasis
6
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Figure 1.1: Bone structure.
and function as a mediator for growth factor release. After 3 to 5 days, a repair blastema
(granulation tissue) is formed, consisting of new blood vessels, collagen and cells, like
macrophages, chondrocytes, osteoblasts and osteoclasts. In the course of several weeks,
callus is formed by maturation of extracellular matrix. Callus stabilizes the two fracture
fragments. If stabilization is unsatisfactory, a cartilaginous intermediate will be formed.
This cartilage is replaced by spongy bone. In the early remodelling phase, callus and spongy
bone are replaced by compact bone, which is less cellular. Finally, in the late remodelling
phase, haversian bone is formed and contour and function are restored (Figure 1.2). This
whole activation-resorption-formation process will take between 3 and 6 months6. When
a bony defect is that large, that healing is not possible, the defect is called a critical size
defect. Such a defect can be deﬁned by being the smallest size of a defect which will not
heal spontaneously, when left untreated, for a certain period of time7. For the healing of
critical size defects, bone grafts, bone substitutes or bone tissue engineering techniques are
necessary.
1.5 Tissue engineering
Tissue engineering is deﬁned as an “Interdisciplinary ﬁeld that applies the principles of
engineering and life sciences toward the development of biological substitutes that restore,
maintain, or improve tissue function”8. With regard to the engineering of bone, strategies
implement the generation of bone tissue by pharmaceutical stimulation of the formation of
bone by the use of bone inducing substances and the construction of mesenchymal stem
cell containing devices. These bone inducing substances are known as growth factors,
which are able to modulate undiﬀerentiated mesenchymal cells into osteoprogenitor cells9.
At present, numerous growth factors involved in bone healing have been identiﬁed and
made available by recombinant gene technology. Most importantly the bone morphogenetic
7
Figure 1.2: Bone healing.
proteins (BMPs), which are members of the transforming growth factor-β (TGF-β) super
family, are described. The purpose of hybrid implants is to create a ‘viable’ material, i.e. an
implantable material, incorporating or attracting live cells at implantation, that are treated
by the host as normal tissue matrices and are actively resorbed or remodelled2. Such a
viable material is, for example, composed of patient own osteogenic cells or tissue, loaded
on a synthetic biomaterial. This synthetic biomaterial has a function as a carrier for the
transplanted cells and as a scaﬀold for the formation of new bone tissue. Amongst the
known growth factors, as previously mentioned, BMPs have proven to possess potential for
enhancing bone formation15. The clinical use of these recombinant BMPs, however, is still
limited. Apart from the fact that they are relatively expensive, they are also only eﬀective
in very high concentrations because they tend to be broken down rather quickly. There is
also a need to use several diﬀerent factors, since in the natural process of bone formation
a whole cascade of combinations of growth factors is responsible for osteoblastic activity.
This has lead to a search for cost-eﬀective alternatives, i.e. naturally derived growth factors,
which could overcome the drawbacks of recombinant versions.
1.6 COLLOSS R©E
Such a natural source, containing BMPs, is already available for clinical use and is obtain-
able in two diﬀerent products (OSSACUR AG, Oberstenfeld, Germany). COLLOSS R© is a
lyophilized complex of the extracellular matrix proteins extracted from diaphyseal bovine
bone, containing native BMPs. In vivo studies have already proved the osteoinductive ca-
pacity of this material, showing bone formation when ectopically implanted16. There even
is a clinical report of the successful use of a combination of lyophilized cartilage and bovine
BMP for reconstructive purposes in the cranio-maxillo-facial area14. Clinical application of
these bovine materials in humans is an issue of discussion, because of the risk of transmis-
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sible spongiform encephalopathy (TSE) infection18. To overcome this problem, a similar
equine material, containing native BMPs, was recently prepared, COLLOSS R©E. Till present,
there is no TSE known in horses. COLLOSS R©E is a natural mixture of growth factors and
is supposed to contain several BMP’s and other growth factors in a collagenous matrix,
consisting of Type I collagen chains.
1.7 Objectives and hypothesis
The main objective of this thesis was to evaluate the potential of natural equine growth
factors, as present in COLLOSS R©E, for reconstructive purposes. The hypothesis is that
COLLOSS R©E will act as an osteoinductive material when applied in combination with a
bone substitute and will have a beneﬁcial eﬀect on the healing of bone in the maxillofacial
area. For this reason, the following questions had to be answered:
1. What bone substitutes and growth factors are currently available for the purpose of
bone tissue engineering?
2. Which diﬀerent growth factors are present in COLLOSS R©E and what is their action
in an in vitro cell culture experiment?
3. Will COLLOSS R©E act as an osteoinductive material when implanted in an ectopic
site, using a small animal model?
4. What is the eﬀect of the use of a biodegradable carrier on the osteoinductivity of
COLLOSS R©E?
5. Is it possible to use COLLOSS R©E to promote bone formation in orthotopic defects
in large animals?
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Bone substitutes and growth factors in reconstructive surgery of the maxillofacial skeleton
2.1 Introduction
Bone grafts are commonly used in oral and maxillofacial reconstructive surgery to restore
oral function or to improve esthetics. For this purpose, autogenous bone grafts are generally
considered to be the gold standard64,30. A major drawback of autogenous bone is, of course,
the need for harvesting, which goes along with donor site morbidity, extended surgical
operating time and a limited quantity of material available. In order to circumvent these
problems, researchers have been trying to identify bone substitutes for many years. The
ideal substitute should mimic the unique properties of autogenous bone, in that it should
be osteoconductive, osteoinductive and also osteogenic. Osteoconduction is a phenomenon
in which there is an ingrowth of sprouting capillaries, perivascular mesenchymal tissues and
osteoprogenitor cells from the recipient host bed into the three-dimensional structure of an
implant or graft.
The osteoconductive capacity of bone is explained by the fact that bone mainly consists of
a calciumphospate mesh, which functions as the three-dimensional structure in which bone
forming cells can grow.
The term osteoinduction refers to a phenomenon in which there is a mitogenesis of un-
diﬀerentiated perivascular mesenchymal cells, leading to the formation of osteoprogenitor
cells with the capacity to form new bone1. After transplantation of a bone graft, formed
regulator proteins are responsible for recruiting surrounding mesenchymal cells and diﬀer-
entiating them into osteoblasts9. The ultimate proof for the osteoinductive capacity of a
bone substitute, is delivered by bone formation in an ectopic site, for example in muscle or
skin tissue.
Autogenous bone is also osteogenic, which indicates the presence of vital osteoblasts within
the bone graft, responsible for the formation of new bone39. This paper presents an overview
of the bone substitutes and growth factors available for possible use in bone tissue engi-
neering.
2.2 Bone substitutes
2.2.1 Allogenic and xenogenic bone
An alternative for autogenous bone may be allogenic and xenogenic bone. Allogenic bone
will be causing immunological reactions, which ultimately will lead to rejection of the graft
and, therefore, needs preparation to become acceptable. For this reason it may be radiated,
freeze dried, demineralised or treated chemically. These treatments, however, eﬀect the
quality of the graft, in that the inductive capacity decreases34. Allogenic bone will not have
vital bone cells and the revascularisation is also less abundant as compared to autogenous
bone. It will also be resorbed faster as compared to autogenous bone grafts25. It requires
extensive screening on various diseases of the donor, which, should reduce the chance of
infection, but this can certainly not be completely ruled out.
Xenografts need preparation to remove all possible antigens for obvious reasons. As a result
only the calcium phosphate skeleton remains which at best will be osteoconductive13,23,52.
There are several of these products available such as, Bio-Oss R© and Osteograf/N R©. Any
xenograft, especially of cows and some other animals, carries the remote risk of contami-
nation with prions that cause transmissable spongiform encephalopathy (TSE)42,95.
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2.2.2 Synthetic bone substitutes
The use of synthetic bone substitutes dates back to the 19th century, in that plaster of
Paris was used for this purpose. This material, however, tends to resorb fast and usually
disappears within a matter of weeks. Since then, more than 50 diﬀerent synthetic bone
substitutes have been described and evaluated in mostly animal experiments25. There are
currently three types of synthetic bone substitutes used, including polymers, bioglass and
calciumphosphates50.
Polymers have never been used at a large scale. Examples are Polyactive
TM
(polyethylene
glycol, polybutylene terephtalate) and Bioplant HTR
TM
: a composite of polymethylmetacry-
late, polyhydroxylethylmethacrylate and calciumhydroxide.
Bioglass consists of calcium salts, phosphates, sodium salts and silicates. When in contact
with tissue ﬂuids a double layer is formed existing of a silica gel and a layer of apatite
rich calcium and phosphates. When the particles are within a range of 300 to 355μm, bone
formation is possible, starting from within the particles, that are hollowed out by phagocytes
that have penetrated the double layer. This phenomenon does not happen when the particles
are bigger, whereas smaller particles give rise to inﬂammatory reactions75.
The bone substitutes based on calciumphosphates can be divided in two groups, resorbable
tricalciumphosphate (TCP) and non-resorbable hydroxylapatite (HA). Tricalciumphosphate
is a porous form of calciumphosphate and fast resorbing, but its mechanical properties are
rather weak as compared to hydroxylapatite. Clinical research results are rather ambiguous
because some studies report about bone ingrowth58, whilst others describe the encasement
of the bone substitute by ﬁbrous tissue2. It has an osteoconductive capacity, but mixed with
particulate autogenous bone, it will only temporarily act as a scaﬀold, since it will disappear
within 6 months. Tricalciumphosphate particles have been used as a material to augment
the ﬂoor of the sinus. Bone formation appeared to occur, but was slower as compared to
autogenous bone grafts102,104.
Hydroxylapatite is an anorganic material that chemically resembles the calcium phosphates
of bone, the primary mineral component of bone. This material also is only osteoconductive
but has the additional advantage that it acts as a scaﬀold, maintaining the volume of
the graft, when mixed with autogenous bone37,74. As of the beginning of the sixties,
hydroxylapatite has been subject of many experiments. It is available in a porous and non-
porous form. By changing the temperature in the production process these various forms
may be achieved. The porous form has the major advantage that it facilitates the ingrowth
of capillaries, which is the ﬁrst step in the healing process. The clinical research done with
hydroxylapatite exceeds that of all other bone substitutes61,4.
Unfortunately, osteogenic bone substitutes have not been produced. Loading bone substi-
tutes, however, with growth factors and bone forming cells is a step forward in creating
osteogenic bone substitutes. This technique is often used in bone engineering.
2.3 Growth factors
Urist already showed in 1965, that demineralised bone, i.e. just the protein component of
bone, can produce bone when implanted in a subcutaneous recipient site88. This ectopic
bone formation had to be induced by a substance that was capable of modifying undiﬀer-
entiated mesenchymal cells into osteoprogenitor cells. It took almost 20 years before this
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substance was identiﬁed as a protein called “bone morphogenic protein”(BMP)89. At the
end of the eighties BMP was extracted from the long bones of cows and puriﬁed which
produced 1μg BMP/kg bone (10−7%)72. In 1990, human BMP (OP-1) was ﬁrst cloned,
followed by the creation of recombinant human BMP (rhOP-1)68,73. At present, many
growth factors have been identiﬁed, but their action in each step of proliferation and diﬀer-
entiation is not completely understood44. The skeleton is the main source of these growth
factors and they are released after a trauma or when bone is remodelling14,35. Since it is
known that growth factors can stimulate bone growth, several of these factors have been
produced by making use of the recombinant gene technology like ‘bone morphogenetic pro-
teins’ (BMPs), ‘ﬁbroblast growth factors’(FGFs), ‘platelet-derived growth factors’(PDGFs),
‘transforming growth factors-β’(TGFs-β) and ‘vascular endothelial growth factor’(VEGF).
The clinical application, however, is somewhat limited because of the fact that relatively
large quantities are necessary, which makes them rather expensive. This is augmented
by the fact that relatively more growth factors are necessary when applied in human be-
ings, as compared to small animals, whilst the healing process in human beings also takes
longer8. Although several clinical studies have been done, the American Food and Drug
Administration (FDA) has not yet approved the wide spread clinical use of members of
the TGF-β superfamily11,31. Since recombinant growth factors are extremely expensive,
researchers have been looking into naturally derived growth factors such as COLLOSS R©
and COLLOSS R©E and autogenous growth factors like platelet rich plasma (PRP) that are
more readily available and would circumvent the cumbersome production problems27,91,59.
In this context it is of interest to note that already in 1994 Sailer and Kolb reported on the
clinical application of BMP extracted from bovine long bones. They showed acceleration
of ossiﬁcation and calciﬁcation of lyophilized cartilage grafts in combination with BMP in
reconstructions of the skull and maxillofacial area.
2.3.1 Bone morphogenetic proteins (BMPs)
BMPs consist of a group of at the least 20 growth factors, which play a role in the formation
of bone, but also in the embryological development. BMP signal transduction is induced by
interaction with the heterodimeric complex of two transmembrane serine/threonine kinase
receptors that is identical to that of TGF-β 100. Although the molecular mechanisms un-
derlying osteoblastic diﬀerentiation remain to be identiﬁed, BMPs play an important role in
regulating osteoblast diﬀerentiation and subsequent bone formation68. Particularly BMP-2,
-4 and -7 seem to be important in that they stimulate undiﬀerentiated mesenchymal cells to
form osteoprogenitor cells. Cheng et al.19, however, suggested that BMP-2, -6 and -9 have
the most potent osteogenic activity. BMP-2 through BMP-9 belong to the transforming
growth factor beta superfamily proteins on the basis of their similar amino acid sequences77.
The transforming growth factor beta superfamily also contains activins, inhibins and TGF-
βs. BMP is a low-molecular-weight non-collagenous glycoprotein and its primary structure
is 40-50% similar to that of TGF-β 87. BMPs are synthesized as large precursor molecules,
that consist of a signal peptide, a prodomain and a carboxy-terminal region of 100-1250
amino acids. BMPs are present in bone matrix, dentin matrix, osteosarcoma and other
tissues and they can be isolated from dematerialized bone matrix (DBM) and are so called
puriﬁed or native BMPs. In the 1960s, Urist obtained BMPs by purifying demineralized
bone matrix.
The preferred method for obtaining BMP is the use of cloning techniques to make recom-
binant BMPs, which can be produced in large quantities96. This method of production
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ensures a pure form of a single speciﬁc BMP. The currently available recombinant human
(rh) BMPs are rhBMP-2 and rhBMP-7. Several animal studies conﬁrmed that rh-BMPs are
clearly osteoinductive and have been used successfully in spine fusion and fracture healing40.
The most important capacity of the BMPs is the fact that they stimulate the diﬀerentiation
of undiﬀerentiated cells into the chondroblastic and osteoblastic phenotype and inhibit the
adipocyte and myogenic diﬀerentiation. Both the concentration of BMP and the duration
of its action aﬀects diﬀerentiation92. The biological functions of BMPs are mainly related
to the formation of bone and cartilage. BMP-8b, -10 and -15, however, do not play any
role in bone or cartilage. BMP-8b is involved in reproductive cells, BMP-10 in cardiac
development and BMP-15 in ovarian physiology. BMP-2 to -11 are considered to be BMPs,
BMP-12, -13 and -14 are named cartilage-derived morphogenetic proteins and BMP-1 is
not even a member of the BMP family, since it was a misidentiﬁed protein with chordinase
and procollagen proteinase activities6.
Administration of BMPs in vitro to human mesenchymal cells resulted in increased matrix
production, alkaline phosphatase and collagen type I98. BMPs, however, did not increase
the proliferation of these cells, which indicates that BMPs act mainly on the morphogenese
and are not mitogenetic on undiﬀerentiated mesenchymal cells12. Administration of BMPs
in vivo caused recruitment of undiﬀerentiated mesenchymal cells and production of extra-
cellular matrix67. Till present, there are, however, rather few clinical studies to attest to
the usefulness of its application in oral and maxillofacial surgery. For instance, in a study
on sinus ﬂoor augmentation only one out of three sinuses appeared to be ﬁlled with min-
eralized tissue5. The use of a higher doses seems to be more eﬀective, in that more bone
was seen7. Another study showed a beneﬁcial eﬀect when BMP-2 was applied in empty
extraction alveoli. This study, however, is seriously impaired by the lack of controls22. Mus-
sano et al., conducted a systematic review of human randomized controlled clinical trials
on BMPs. They concluded that in procedures of interbody fusion of lumbar vertebrae, the
use of BMPs appeared to improve eﬃcacy versus traditional techniques, harvesting bone,
slightly57. BMP-2 and -7 are presently approved for clinical use in open fractures of long
bones, non-union and spinal fusion28.
2.3.2 Transforming growth factor-β
Transforming growth factor-β ( TGF-β) belongs to a large family of related molecules, i.e.
mu¨llerian inhibiting substance, inhibin, activin and bone morphogenetic protein. It was
originally discovered by de Larco et al.41 as a peptide that was produced by sarcoma virus-
transformed mouse ﬁbroblasts. The name transforming growth factor is derived, therefore,
from the fact that they were thought to transform normal cells into neoplastic cells, as
they were originally detected in tumor extracts16. TGF-β is a 25 kilodalton (kDa) dimeric
polypeptide that consists of 112 amino acids and is known to exist in at least ﬁve diﬀerent
isoforms with 65-80% homology to each other.81,70. Three isoforms of TGF-β exist in
mammals, i.e. TGF-β1, -2 and -343. TGF-β1 was originally puriﬁed from human platelets.
TGF-β2 was isolated form bovine bone, human glioblastoma cells and porcine platelets.
TGF-β3 has been cloned and was also found in chicken. TGF-β4 has been described in
chickens, whereas TGF-β5 was found in frogs82. The growth factors are secreted by most
cell types, generally in a latent form, requiring activation before they can exert biological
activity. This activation of latent TGF-β appears to be a crucial regulatory step in controlling
their eﬀect. TGF-β is present mostly in platelets and bone44 from which it has been
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isolated, but it can also be produced by using molecular cloning techniques46. Almost
all cells have surface receptors for TGF-β 90 but osteoblasts possess the highest number of
TGF-β receptors71. The TGF-β receptors are cell-surface serine/threonine kinase receptors.
Three types of TGF-β receptors are distinguished, i.e. type-I, type-II and betaglycan which
was previously termed type-III. After binding of TGF-β to the receptor, signaling occurs
through the Smad pathway97.
TGF-β is not a bone inducing protein, but plays in vivo an important role in wound heal-
ing by enhancing the repair of injured tissue like skin and bone43. The TGF-βs possess
three major activities. At ﬁrst they inhibit proliferation of most cells, but can stimulate
growth of some mesenchymal cells, including osteoblasts, ﬁbroblasts and chondroblasts.
Secondly, they exert immunosuppressive eﬀects by inhibiting the proliferation of T- and
B-lymphocytes. Thirdly, they enhance the formation of extracellulair matrix, i.e. collagen,
ﬁbronectin, glycosaminoglycans and proteoglycans. Inhibition of growth by TGF-β results
from a blockage of the cell cycle in the late G1 phase43. TGF-β acts on osteoblasts, chon-
drocytes and cells of the osteoblastic lineage as well as on other cells17. In bone cells,
both stimulating and inhibiting eﬀects have been described for cellular diﬀerentiation and
proliferation: low concentrations stimulate proliferation and high concentrations inhibit it71.
In more diﬀerentiated cell cultures, TGF-β stimulates the synthesis of type-I collagen and
suppresses alkaline phosphatase activity18. TGF-β inhibits the formation of osteoclast-like
cells in vitro and decreases bone resorption in bone organ cultures18. Dieudonne et al.
found the mineral resorbing eﬀect of TGF-β to be biphasic, i.e. low concentrations stim-
ulate while higher concentrations inhibit26. TGF-β is also found to act as a chemotactic
factor for ﬁbroblasts65.
In several animal experiments, TGF-β has been evaluated in cranial, mandibular, radial
and tibial defects for its use in reconstructive surgery. The results were ambigious with
regard to bone regeneration. The addition of TGF-β1 alone in alveolar and skeletal defects
in rats, baboons and dogs, did not reveal any acceleration of bone formation10,69,84. In
other studies, however, in orthoptic sites in rat and mice, TGF-β1 and TGF-β2 have been
found to stimulate osteogenesis60,36. TGF-β1 also enhanced the osseointegration of metal
implants in dogs44. The enhancement of bone healing by TGF-β1 seems to depend on the
carrier material used99 and to be dose dependent within a certain range. However, a higher
concentration does not necessarily result in the formation of more bone3.
2.3.3 Fibroblast growth factor (FGF)
Until now, two diﬀerent FGF factors have been identiﬁed, i.e. acidic (aFDF) and basic
(bFGF). Fibroblast growth factors stimulate mitogenesis of ﬁbroblasts, chondrocytes and
osteoblasts, in particular bone collagen and cartilage are formed. They also stimulate the
angiogenesis, a very important event in the healing process44.
2.3.4 Platelet-rich plasma (PRP)
PRP is derived from blood plasma and consists of a high concentration of platelets achieved
by spinning. According to Marx, the eﬀective concentration is about 5x the normal con-
centration48. PRP contains at the least four growth factors, including Platelet derived
growth factors (PDGFs), TGF-β1, vascular endothelial growth factor (VEGF) and insulin-
like growth factor (IGF).
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Platelet derived growth factors (PDGFs) are not osteogenic, but enhance bone formation in
conjunction with other growth factors77. Their mode of action is stimulation of mitogenic
activity of bone cells and stimulation of chemotaxis on mesenchymal cells and osteoblasts. In
bone regeneration PDGF might be suitable as a co-factor, by utilizing its strong chemotactic
capacity for osteoblasts45 in combination with other growth factors, like insulin-like growth
factor47. Research on its potential action with and without the addition of IGF-1, revealed
bone ingrowth in periodontal defects29,32.
Insulin–like growth factor (IGF) is the most abundantly stored growth factor in bone ma-
trix54. It has a direct stimulating eﬀect on bone formation by stimulating the growth of
osteoprogenitor cells, but their role is not completely understood78. Its application alone
has not yet shown any acceleration of bone growth in the facial skeleton in the reported
dosages77.
Vascular endothelial growth factor (VEGF) plays an important role in the angiogenesis and
is the most important component of the regeneration of the vascular system in fracture
healing. VEGF mediates the capillary invasion that is necessary for the complex process
of endochondral ossiﬁcation. VEGF also promotes the diﬀerentiation of osteoblasts and
increases the mineralisation of the regenerated bone38.
PRP stimulates the angiogenesis and the production of both ﬁbroblasts and osteoblasts,
whilst it inhibits bone resorption. Most authors have used autogenous PRP by extracting
it from donations done by the patients. There is no consensus in literature on the clinical
usefulness of PRP, although its osteoinductive capacity has been determined48. There
are many publications on the use of PRP, both including animal experiments27,62,56,63 and
clinical studies94,49,86,66,85,79,24. Some animal experiments showed positive results on bone
healing when combining PRP with autogenous bone, but no eﬀects were seen when PRP
was combined with bone substitutes. Other animal studies revealed negative results on the
use of PRP in relation to bone regeneration. The reasons for these variable results are not
completely clear, but Mooren et al.55 point towards a possible explanation, in that diﬀerent
from human beings, animals have a great variation in the number of platelets and also the
morphology is quite diverse. This makes it diﬃcult to achieve consistent concentrations
that will be eﬀective.
2.4 Tissue engineering
Tissue engineering applies principles of biology and engineering to the development of func-
tional substitutes for damaged tissue. The ultimate goal of tissue engineering is to produce
tissue at the desired location that is functional and, thus, replaces the traditional autoge-
nous grafts with their known disadvantages. With regard to bone, it implies that the focus
of the research is directed towards growth factors, bone substitutes as carriers (scaﬀolds)
for growth factors and vital mesenchymal cells that can diﬀerentiate into osteoblasts51. Till
present, only little progress has been made, in that there are only four studies published that
report on more or less successful clinical applications15,76,93. A very promising technique has
recently been published by Mesima¨ki et al53. They described the ﬁrst clinical case, in which
ectopic bone was successfully produced, utilizing autologous adipose stem cells, β-TCP and
BMP-2. After 8 months, the ectopic bone graft could be successfully transplanted into a
bony defect area.
The above mentioned examples of tissue engineering are based on chemical stimulation,
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but an alternative could be mechanical stimulation. This principle is applied when using
distraction osteogenesis. This is a process in which new bone formation is gradually induced
by an opening device between two bony surfaces33,83. The combination of the distraction
osteogenesis technique and synthetic bone substitutes, with and without growth factors, is
a new ﬁeld of interest. Several experiments have been done, using this combination, but
with various results21,80,20,101,103.
References
[1] Albrektsson T and Johansson C. Osteoinduction, osteoconduction and osseointegra-
tion. Eur Spine J, 2001; 10 Suppl 2: S96–101.
[2] Amler M. Osteogenic potential of nonvital tissues and synthetic implant materials. J
Periodontol, 1987; 58(11): 758–761.
[3] Beck L, Amento E, Xu Y, Deguzman L, Lee W, Nguyen T and Gillett N. Tgf-beta 1
induces bone closure of skull defects: temporal dynamics of bone formation in defects
exposed to rhtgf-beta 1. J Bone Miner Res, 1993; 8(6): 753–761.
[4] Beekmans H, Meijer G, Barkhuysen R, Blijdorp P, Merkx M and Jansen J. The
hydroxylapatite-bone interface: 10 years after implant installation. Int J Oral Max-
illofac Surg, 2008; 37(8): 768–772.
[5] van den Bergh J, ten Bruggenkate C, Groeneveld H, Burger E and Tuinzing D. Re-
combinant human bone morphogenetic protein-7 in maxillary sinus ﬂoor elevation
surgery in 3 patients compared to autogenous bone grafts. a clinical pilot study. J
Clin Periodontol, 2000; 27(9): 627–636.
[6] Bessa P, Casal M and Reis R. Bone morphogenetic proteins in tissue engineering: the
road from the laboratory to the clinic, part i (basic concepts). J Tissue Eng Regen
Med, 2008; 2(1): 1–13.
[7] Bianchi J, Fiorellini JP, Howell TH, Sekler J, Curtin H, Nevins ML and Friedland B.
Measuring the eﬃcacy of rhbmp-2 to regenerate bone: a radiographic study using a
commercially available software program. Int J Periodontics Restorative Dent, 2004;
24(6): 579–587.
[8] Boden SD. Biology of lumbar spine fusion and use of bone graft substitutes: present,
future, and next generation. Tissue Eng, 2000; 6(4): 383–399.
[9] Boer FCD, Patka P and Haarman HJ. [bone induction using bone growth factors:
bone morphogenetic proteins]. Ned Tijdschr Geneeskd, 1996; 140(48): 2390–2394.
[10] Bosch C, Melsen B, Gibbons R and Vargervik K. Human recombinant transforming
growth factor-beta 1 in healing of calvarial bone defects. J Craniofac Surg, 1996;
7(4): 300–310.
[11] Boyne PJ, Marx RE, Nevins M, Triplett G, Lazaro E, Lilly LC, Alder M and Num-
mikoski P. A feasibility study evaluating rhbmp-2/absorbable collagen sponge for
maxillary sinus ﬂoor augmentation. Int J Periodontics Restorative Dent, 1997; 17(1):
11–25.
21
[12] Bo¨ttner M, Krieglstein K and Unsicker K. The transforming growth factor-betas:
structure, signaling, and roles in nervous system development and functions. J Neu-
rochem, 2000; 75(6): 2227–2240.
[13] Callan DP and Rohrer MD. Use of bovine-derived hydroxyapatite in the treatment of
edentulous ridge defects: a human clinical and histologic case report. J Periodontol,
1993; 64(6): 575–582.
[14] Canalis E, McCarthy T and Centrella M. Growth factors and the regulation of bone
remodeling. J Clin Invest, 1988; 81(2): 277–281.
[15] Cancedda R, Mastrogiacomo M, Bianchi G, Derubeis A, Muraglia A and Quarto R.
Bone marrow stromal cells and their use in regenerating bone. Novartis Found Symp,
2003; 249: 133–143.
[16] Centrella M and Canalis E. Transforming and nontransforming growth factors are
present in medium conditioned by fetal rat calvariae. Proc Natl Acad Sci U S A,
1985; 82(21): 7335–7339.
[17] Centrella M, Horowitz MC, Wozney JM and McCarthy TL. Transforming growth
factor-beta gene family members and bone. Endocr Rev, 1994; 15(1): 27–39.
[18] Centrella M, McCarthy TL and Canalis E. Eﬀects of transforming growth factors on
bone cells. Connect Tissue Res, 1989; 20(1-4): 267–275.
[19] Cheng H, Jiang W, Phillips FM, Haydon RC, Peng Y, Zhou L, Luu HH, An N, Breyer
B, Vanichakarn P, Szatkowski JP, Park JY and He TC. Osteogenic activity of the
fourteen types of human bone morphogenetic proteins (bmps). J Bone Joint Surg
Am, 2003; 85-A(8): 1544–1552.
[20] Cho BC, Chung HY, Lee DG, Yang JD, Park JW, Roh KH, Kim GU, Lee DS, Kwon IC,
Bae EH, Jang KH, Park RW and Kim IS. The eﬀect of chitosan bead encapsulating
calcium sulfate as an injectable bone substitute on consolidation in the mandibular
distraction osteogenesis of a dog model. J Oral Maxillofac Surg, 2005; 63(12):
1753–1764.
[21] Cho BC, Park JW, Baik BS, Kwon IC and Kim IS. The role of hyaluronic acid,
chitosan, and calcium sulfate and their combined eﬀect on early bony consolidation
in distraction osteogenesis of a canine model. J Craniofac Surg, 2002; 13(6): 783–
793.
[22] Cochran DL, Jones AA, Lilly LC, Fiorellini JP and Howell H. Evaluation of recom-
binant human bone morphogenetic protein-2 in oral applications including the use of
endosseous implants: 3-year results of a pilot study in humans. J Periodontol, 2000;
71(8): 1241–1257.
[23] Cohen RE, Mullarky RH, Noble B, Comeau RL and Neiders ME. Phenotypic charac-
terization of mononuclear cells following anorganic bovine bone implantation in rats.
J Periodontol, 1994; 65(11): 1008–1015.
[24] Consolo U, Zaﬀe D, Bertoldi C and Ceccherelli G. Platelet-rich plasma activity on
maxillary sinus ﬂoor augmentation by autologous bone. Clin Oral Implants Res, 2007;
18(2): 252–262.
22
REFERENCES
[25] Damien CJ and Parsons JR. Bone graft and bone graft substitutes: a review of
current technology and applications. J Appl Biomater, 1991; 2(3): 187–208.
[26] Dieudonne´ SC, Foo P, van Zoelen EJ and Burger EH. Inhibiting and stimulating eﬀects
of tgf-beta 1 on osteoclastic bone resorption in fetal mouse bone organ cultures. J
Bone Miner Res, 1991; 6(5): 479–487.
[27] Fennis JPM, Stoelinga PJW and Jansen JA. Mandibular reconstruction: a clinical
and radiographic animal study on the use of autogenous scaﬀolds and platelet-rich
plasma. Int J Oral Maxillofac Surg, 2002; 31(3): 281–286.
[28] Gautschi OP, Frey SP and Zellweger R. Bone morphogenetic proteins in clinical
applications. ANZ J Surg, 2007; 77(8): 626–631.
[29] Giannobile WV, Hernandez RA, Finkelman RD, Ryan S, Kiritsy CP, D’Andrea M
and Lynch SE. Comparative eﬀects of platelet-derived growth factor-bb and insulin-
like growth factor-i, individually and in combination, on periodontal regeneration in
macaca fascicularis. J Periodontal Res, 1996; 31(5): 301–312.
[30] Goh BT, Lee S, Tideman H and Stoelinga PJW. Mandibular reconstruction in adults:
a review. Int J Oral Maxillofac Surg, 2008; 37(7): 597–605.
[31] Groeneveld EH, van den Bergh JP, Holzmann P, ten Bruggenkate CM, Tuinzing DB
and Burger EH. Histomorphometrical analysis of bone formed in human maxillary
sinus ﬂoor elevations grafted with op-1 device, demineralized bone matrix or autoge-
nous bone. comparison with non-grafted sites in a series of case reports. Clin Oral
Implants Res, 1999; 10(6): 499–509.
[32] Howell TH, Fiorellini JP, Paquette DW, Oﬀenbacher S, Giannobile WV and Lynch
SE. A phase i/ii clinical trial to evaluate a combination of recombinant human
platelet-derived growth factor-bb and recombinant human insulin-like growth factor-i
in patients with periodontal disease. J Periodontol, 1997; 68(12): 1186–1193.
[33] Ilizarov GA. The tension-stress eﬀect on the genesis and growth of tissues: Part ii.
the inﬂuence of the rate and frequency of distraction. Clin Orthop Relat Res, 1989;
(239): 263–285.
[34] Iwata H, Hanamura H, Kaneko M, Yasuhara N, Terashima Y, Kajino G, Ida K,
Mabuchi Y and Nakagawa M. Chemosterilized autolyzed antigen-extracted allogeneic
(aaa) bone matrix gelatin for repair of defects from excision of benign bone tumors:
a preliminary report. Clin Orthop Relat Res, 1981; (154): 150–155.
[35] Joyce M, Jingushi S, Scully P and Bolander M. Role of growth factors in fracture
healing. In W Aeglestein, M Caldwell, D Marshall and A Barbul, eds., Clinical and ex-
perimental approaches to dermal and epidermal repair: Normal and Chronic Wounds,
pp. 391–416. New York: Wiley-Liss Inc, 1991; .
[36] Joyce ME, Roberts AB, Sporn MB and Bolander ME. Transforming growth factor-
beta and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell
Biol, 1990; 110(6): 2195–2207.
[37] Kent J and Jarcho. Reconstruction of the alveolar ridge witg hydroxylapatite. In
Fonesca and Davis, eds., Reconstructive preprosthetic oral and maxillofacial surgery,
23
pp. 305–346. W.B. Saunders Company: West Washington Square Philadelphia, 1986;
.
[38] Keramaris NC, Calori GM, Nikolaou VS, Schemitsch EH and Giannoudis PV. Fracture
vascularity and bone healing: a systematic review of the role of vegf. Injury, 2008;
39 Suppl 2: S45–S57.
[39] Kruyt MC, Dhert WJA, Oner C, van Blitterswijk CA, Verbout AJ and de Bruijn JD.
Osteogenicity of autologous bone transplants in the goat. Transplantation, 2004;
77(4): 504–509.
[40] Lane JM. Bone morphogenic protein science and studies. J Orthop Trauma, 2005;
19(10 Suppl): S17–S22.
[41] de Larco JE and Todaro GJ. Growth factors from murine sarcoma virus-transformed
cells. Proc Natl Acad Sci U S A, 1978; 75(8): 4001–4005.
[42] Lasme´zas CI. The transmissible spongiform encephalopathies. Rev Sci Tech, 2003;
22(1): 23–36.
[43] Lawrence DA. Transforming growth factor-beta: a general review. Eur Cytokine
Netw, 1996; 7(3): 363–374.
[44] Lind M. Growth factors: possible new clinical tools. a review. Acta Orthop Scand,
1996; 67(4): 407–417.
[45] Lind M, Deleuran B, Thestrup-Pedersen K, Søballe K, Eriksen EF and Bu¨nger C.
Chemotaxis of human osteoblasts. eﬀects of osteotropic growth factors. APMIS,
1995; 103(2): 140–146.
[46] Lioubin MN, Madisen L, Marquardt H, Roth R, Kovacina KS and Purchio AF. Char-
acterization of latent recombinant tgf-beta 2 produced by chinese hamster ovary cells.
J Cell Biochem, 1991; 45(1): 112–121.
[47] Lynch SE, Buser D, Hernandez RA, Weber HP, Stich H, Fox CH and Williams RC.
Eﬀects of the platelet-derived growth factor/insulin-like growth factor-i combination
on bone regeneration around titanium dental implants. results of a pilot study in
beagle dogs. J Periodontol, 1991; 62(11): 710–716.
[48] Marx RE. Platelet-rich plasma (prp): what is prp and what is not prp? Implant Dent,
2001; 10(4): 225–228.
[49] Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE and Georgeﬀ KR.
Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral
Med Oral Pathol Oral Radiol Endod, 1998; 85(6): 638–646.
[50] Meijer G. Alternatieven voor autoloog bot; een introductie. In M Cune and G Mei-
jer, eds., Implantologie in partieel dentate situaties, pp. 101–104. Bohn Staﬂeu van
Loghum, 2003; .
[51] Meijer GJ, de Bruijn JD, Koole R and van Blitterswijk CA. Cell based bone tissue
engineering in jaw defects. Biomaterials, 2008; 29(21): 3053–3061.
[52] Merkx MA, Maltha JC, Freihofer HP and Kuijpers-Jagtman AM. Incorporation of
particulated bone implants in the facial skeleton. Biomaterials, 1999; 20(21): 2029–
2035.
24
REFERENCES
[53] Mesima¨ki K, Lindroos B, To¨rnwall J, Mauno J, Lindqvist C, Kontio R, Miettinen S
and Suuronen R. Novel maxillary reconstruction with ectopic bone formation by gmp
adipose stem cells. Int J Oral Maxillofac Surg, 2009; 38(3): 201–209.
[54] Mohan S and Baylink DJ. Evidence that the inhibition of te85 human bone cell
proliferation by agents which stimulate camp production may in part be mediated by
changes in the igf-ii regulatory system. Growth Regul, 1991; 1(3): 110–118.
[55] Mooren R, Dankers C, Merkx M, Bronkhorst E, Jansen J and Stoelinga P. The eﬀect
of platelet-rich plasma on early and late bone healing using a mixture of particulate
autogenous cancellous bone and bio-oss r: an experimental study in goats. Int J Oral
Maxillo Fac Surg ; Accepted November 2009.
[56] Mooren RECM, Merkx MAW, Bronkhorst EM, Jansen JA and Stoelinga PJW. The
eﬀect of platelet-rich plasma on early and late bone healing: an experimental study
in goats. Int J Oral Maxillofac Surg, 2007; 36(7): 626–631.
[57] Mussano F, Ciccone G, Ceccarelli M, Baldi I and Bassi F. Bone morphogenetic
proteins and bone defects: a systematic review. Spine (Phila Pa 1976), 2007; 32(7):
824–830.
[58] Nasr HF, Aichelmann-Reidy ME and Yukna RA. Bone and bone substitutes. Peri-
odontol 2000, 1999; 19: 74–86.
[59] Nienhuijs MEL, Walboomers XF, Merkx MAW, Stoelinga PJW and Jansen JA. Bone-
like tissue formation using an equine colloss e-ﬁlled titanium scaﬀolding material.
Biomaterials, 2006; 27(16): 3109–3114.
[60] Noda M and Camilliere JJ. In vivo stimulation of bone formation by transforming
growth factor-beta. Endocrinology, 1989; 124(6): 2991–2994.
[61] Perry CR. Bone repair techniques, bone graft, and bone graft substitutes. Clin Orthop
Relat Res, 1999; (360): 71–86.
[62] Plachokova AS, van den Dolder J, Stoelinga PJ and Jansen JA. The bone regenerative
eﬀect of platelet-rich plasma in combination with an osteoconductive material in rat
cranial defects. Clin Oral Implants Res, 2006; 17(3): 305–311.
[63] Plachokova AS, van den Dolder J, Stoelinga PJ and Jansen JA. Early eﬀect of platelet-
rich plasma on bone healing in combination with an osteoconductive material in rat
cranial defects. Clin Oral Implants Res, 2007; 18(2): 244–251.
[64] Pogrel MA, Podlesh S, Anthony JP and Alexander J. A comparison of vascularized
and nonvascularized bone grafts for reconstruction of mandibular continuity defects.
J Oral Maxillofac Surg, 1997; 55(11): 1200–1206.
[65] Postlethwaite AE, Seyer JM and Kang AH. Chemotactic attraction of human ﬁbrob-
lasts to type i, ii, and iii collagens and collagen-derived peptides. Proc Natl Acad Sci
U S A, 1978; 75(2): 871–875.
[66] Raghoebar GM, Schortinghuis J, Liem RSB, Ruben JL, van der Wal JE and Vissink
A. Does platelet-rich plasma promote remodeling of autologous bone grafts used for
augmentation of the maxillary sinus ﬂoor? Clin Oral Implants Res, 2005; 16(3):
349–356.
25
[67] Reddi AH. Cartilage-derived morphogenetic proteins and cartilage morphogenesis.
Microsc Res Tech, 1998; 43(2): 131–136.
[68] Reddi AH. Bone morphogenetic proteins: from basic science to clinical applications.
J Bone Joint Surg Am, 2001; 83-A Suppl 1(Pt 1): S1–S6.
[69] Ripamonti U, Bosch C, van den Heever B, Duneas N, Melsen B and Ebner R. Limited
chondro-osteogenesis by recombinant human transforming growth factor-beta 1 in
calvarial defects of adult baboons (papio ursinus). J Bone Miner Res, 1996; 11(7):
938–945.
[70] Roberts AB, Flanders KC, Heine UI, Jakowlew S, Kondaiah P, Kim SJ and Sporn
MB. Transforming growth factor-beta: multifunctional regulator of diﬀerentiation
and development. Philos Trans R Soc Lond B Biol Sci, 1990; 327(1239): 145–154.
[71] Robey PG, Young MF, Flanders KC, Roche NS, Kondaiah P, Reddi AH, Termine
JD, Sporn MB and Roberts AB. Osteoblasts synthesize and respond to transforming
growth factor-type beta (tgf-beta) in vitro. J Cell Biol, 1987; 105(1): 457–463.
[72] Sampath TK, Coughlin JE, Whetstone RM, Banach D, Corbett C, Ridge RJ, Ozkay-
nak E, Oppermann H and Rueger DC. Bovine osteogenic protein is composed of
dimers of op-1 and bmp-2a, two members of the transforming growth factor-beta
superfamily. J Biol Chem, 1990; 265(22): 13198–13205.
[73] Sampath TK, Maliakal JC, Hauschka PV, Jones WK, Sasak H, Tucker RF, White
KH, Coughlin JE, Tucker MM and Pang RH. Recombinant human osteogenic protein-
1 (hop-1) induces new bone formation in vivo with a speciﬁc activity comparable
with natural bovine osteogenic protein and stimulates osteoblast proliferation and
diﬀerentiation in vitro. J Biol Chem, 1992; 267(28): 20352–20362.
[74] Satow S, Slagter AP, Stoelinga PJ and Habets LL. Interposed bone grafts to accom-
modate endosteal implants for retaining mandibular overdentures. a 1-7 year follow-up
study. Int J Oral Maxillofac Surg, 1997; 26(5): 358–364.
[75] Schepers EJ, Ducheyne P, Barbier L and Schepers S. Bioactive glass particles of
narrow size range: a new material for the repair of bone defects. Implant Dent,
1993; 2(3): 151–156.
[76] Schimming R and Schmelzeisen R. Tissue-engineered bone for maxillary sinus aug-
mentation. J Oral Maxillofac Surg, 2004; 62(6): 724–729.
[77] Schliephake H. Bone growth factors in maxillofacial skeletal reconstruction. Int J
Oral Maxillofac Surg, 2002; 31(5): 469–484.
[78] Schmid C, Guler HP, Rowe D and Froesch ER. Insulin-like growth factor i regulates
type i procollagen messenger ribonucleic acid steady state levels in bone of rats.
Endocrinology, 1989; 125(3): 1575–1580.
[79] Simon ENM, Merkx MAW, Shubi FM, Kalyanyama BM and Stoelinga PJW. Re-
construction of the mandible after ablative surgery for the treatment of aggressive,
benign odontogenic tumours in tanzania: a preliminary study. Int J Oral Maxillofac
Surg, 2006; 35(5): 421–426.
[80] Song HR, Oh CW, Kyung HS, Park IH, Kim PT, Baek SH, Kim SJ and Lee ST.
26
REFERENCES
Injected calcium sulfate for consolidation of distraction osteogenesis in rabbit tibia. J
Pediatr Orthop B, 2004; 13(3): 170–175.
[81] Sporn MB and Roberts AB. Tgf-beta: problems and prospects. Cell Regul, 1990;
1(12): 875–882.
[82] Sporn MB and Roberts AB. The transforming growth factor-betas: past, present,
and future. Ann N Y Acad Sci, 1990; 593: 1–6.
[83] van Strijen PJ, Perdijk FB and Breuning KH. [distraction osteogenesis. a new devel-
opment in craniofacial surgery]. Ned Tijdschr Tandheelkd, 1998; 105(4): 129–131.
[84] Tatakis DN, Wikesjo¨ UM, Razi SS, Sigurdsson TJ, Lee MB, Nguyen T, Ongpipat-
tanakul B and Hardwick R. Periodontal repair in dogs: eﬀect of transforming growth
factor-beta 1 on alveolar bone and cementum regeneration. J Clin Periodontol, 2000;
27(9): 698–704.
[85] Thor A, Wannfors K, Sennerby L and Rasmusson L. Reconstruction of the severely
resorbed maxilla with autogenous bone, platelet-rich plasma, and implants: 1-year
results of a controlled prospective 5-year study. Clin Implant Dent Relat Res, 2005;
7(4): 209–220.
[86] Thorn JJ, Sørensen H, Weis-Fogh U and Andersen M. Autologous ﬁbrin glue with
growth factors in reconstructive maxillofacial surgery. Int J Oral Maxillofac Surg,
2004; 33(1): 95–100.
[87] Urist M. Bone morphogenetic protein in biology and medicine. In T Lindolm, ed.,
Bone Morphogenetic Proteins: Biology, biochemistry and reconstructive surgery, pp.
7–29. Academic press, London UK, 1996; .
[88] Urist MR. Bone: formation by autoinduction. Science, 1965; 150(698): 893–899.
[89] Urist MR, Sato K, Brownell AG, Malinin TI, Lietze A, Huo YK, Prolo DJ, Oklund S,
Finerman GA and DeLange RJ. Human bone morphogenetic protein (hbmp). Proc
Soc Exp Biol Med, 1983; 173(2): 194–199.
[90] Wakeﬁeld LM, Smith DM, Masui T, Harris CC and Sporn MB. Distribution and
modulation of the cellular receptor for transforming growth factor-beta. J Cell Biol,
1987; 105(2): 965–975.
[91] Walboomers XF and Jansen JA. Bone tissue induction, using a colloss-ﬁlled titanium
ﬁbre mesh-scaﬀolding material. Biomaterials, 2005; 26(23): 4779–4785.
[92] Wang EA, Israel DI, Kelly S and Luxenberg DP. Bone morphogenetic protein-2 causes
commitment and diﬀerentiation in c3h10t1/2 and 3t3 cells. Growth Factors, 1993;
9(1): 57–71.
[93] Warnke PH, Springer ING, Wiltfang J, Acil Y, Euﬁnger H, Wehmo¨ller M, Russo PAJ,
Bolte H, Sherry E, Behrens E and Terheyden H. Growth and transplantation of a
custom vascularised bone graft in a man. Lancet, 2004; 364(9436): 766–770.
[94] Whitman DH and Berry RL. A technique for improving the handling of particulate
cancellous bone and marrow grafts using platelet gel. J Oral Maxillofac Surg, 1998;
56(10): 1217–1218.
27
[95] Williams ES and Miller MW. Transmissible spongiform encephalopathies in non-
domestic animals: origin, transmission and risk factors. Rev Sci Tech, 2003; 22(1):
145–156.
[96] Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM
and Wang EA. Novel regulators of bone formation: molecular clones and activities.
Science, 1988; 242(4885): 1528–1534.
[97] Wrana JL and Attisano L. The smad pathway. Cytokine Growth Factor Rev, 2000;
11(1-2): 5–13.
[98] Yamaguchi A, Katagiri T, Ikeda T, Wozney JM, Rosen V, Wang EA, Kahn AJ,
Suda T and Yoshiki S. Recombinant human bone morphogenetic protein-2 stimulates
osteoblastic maturation and inhibits myogenic diﬀerentiation in vitro. J Cell Biol,
1991; 113(3): 681–687.
[99] Yamamoto M, Tabata Y, Hong L, Miyamoto S, Hashimoto N and Ikada Y. Bone
regeneration by transforming growth factor beta1 released from a biodegradable hy-
drogel. J Control Release, 2000; 64(1-3): 133–142.
[100] Yamashita H, Dijke PT, Heldin CH and Miyazono K. Bone morphogenetic protein
receptors. Bone, 1996; 19(6): 569–574.
[101] Zakhary K, Motakis D, Hamdy RH, Campisi P, Amar Y and Lessard ML. Eﬀect of
recombinant human bone morphogenetic protein 7 on bone density during distraction
osteogenesis of the rabbit mandible. J Otolaryngol, 2005; 34(6): 407–414.
[102] Zerbo IR, Zijderveld SA, de Boer A, Bronckers ALJJ, de Lange G, ten Bruggenkate
CM and Burger EH. Histomorphometry of human sinus ﬂoor augmentation using a
porous beta-tricalcium phosphate: a prospective study. Clin Oral Implants Res, 2004;
15(6): 724–732.
[103] Zheng LW, Wong MCM, Rabie ABM and Cheung LK. Evaluation of recombinant hu-
man bone morphogenetic protein-2 in mandibular distraction osteogenesis in rabbits:
Eﬀect of dosage and number of doses on formation of bone. Br J Oral Maxillofac
Surg, 2006; 44(6): 487–494.
[104] Zijderveld SA, Zerbo IR, van den Bergh JPA, Schulten EAJM and ten Bruggenkate
CM. Maxillary sinus ﬂoor augmentation using a beta-tricalcium phosphate (cerasorb)
alone compared to autogenous bone grafts. Int J Oral Maxillofac Implants, 2005;
20(3): 432–440.
28
29


32
Analytical assessment of the osteoinductive material COLLOSS R©E
3.1 Introduction
To repair bony defects, engineering of bone tissue remains a desirable goal as to avoid
the necessity of bone harvests. To produce new bone like tissues, there is a need for
osteoinductive biomaterials. Bone induction by decalciﬁed bone matrix (DBM) was ﬁrst
described by Urist in 196515. He demonstrated the ectopic bone formation due to implanting
DBM subcutaneously in rats. In 1976 Urist was able to isolate a low-molecular protein
fraction from bone and called it bone morphogenetic protein (BMP). In the following years,
more knowledge was acquired about the mechanism of BMP as a growth factor, especially
when recombinant versions became available. The clinical use of these recombinant BMPs,
however, is still limited for a number of reasons. Apart form the fact that they are relatively
expensive, they are only eﬀective in very high concentrations. These high concentrations
are required to compensate for breakdown. There is also a need to use several diﬀerent
factors, since in the natural process of bone formation a whole cascade of combinations
of growth factors is responsible for osteoblastic activity. For these reasons there is great
interest in the use of naturally derived growth factors, which could overcome the drawbacks
of recombinant versions.
COLLOSS R©E (OSSACUR AG, Oberstenfeld, Germany) is such a material, extracted from
the extracellular matrix of equine long bone. Only the compacta of the diaphysis of these
bones were processed. After lyophilization, COLLOSS R©E is a natural growth facture mixture
(GFm) and is supposed to contain several BMPs and other growth factors in a collagenous
matrix, consisting of Type I collagen chains20.
Several animal experiments have shown the osteoinductive capacity of COLLOSS R© (a similar
product derived from bovine source) and COLLOSS R©E in ectopic testing sites16,6,8,17,11,
as well as in orthotoptic sites7. It was shown that both COLLOSS R© and COLLOSS R©E
were equivalent and that they had a similar eﬀect on bone formation. Anterior lumbar
interbody fusion model studies in pigs showed, that both bovine and equine COLLOSS R©
were able to induce the same fusion rate as compared to autogenous bone10,9. Baas et al.
compared COLLOSS R©E, in combination with βTCP granules, with an allograft in terms
of implant ﬁxations in a dog model. They observed a comparable implant ﬁxation but
noticed a diﬀerence in the absence of ﬁbrous tissue and an increase in new bone volume in
the COLLOSS R©E group. They suggested that the reduction of ﬁbrous encapsulation is a
promising advantage of the equine bone collagen material1.
Despite these rather successful results of animal experiments, there still is a fundamental
lack of knowledge on the exact number and quantity of growth factors in COLLOSS R©E.
It seems logical to analyse the contents of COLLOSS R©E before further studies are set
up. The purpose of the present study, therefore, is to determine the presence of diﬀerent
growth factors in COLLOSS R©E. With this knowledge it would be possible to determine the
synergy between the diﬀerent growth factors in various studies14 and to understand the
osteoinductive capacity of COLLOSS R©E.
3.2 Material and methods
3.2.1 COLLOSS R©E Preparation
The manufacturer (OSSACUR AG, Oberstenfeld, Germany) extracted COLLOSS R© material
from the extracellular matrix of bovine or equine long bone (i.e. humerus, radius, metacar-
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Table 3.1: Growth factors examined in this study
Growth factor Function Detection technique
VEGF Vascular endothelial growth factor Angiogenesis ELISA
bFGF basic ﬁbroblast growth factor Angiogenesis ELISA
TGFβ-1 Transforming growth factor-beta 1 Bone formation ELISA, MS/WB
TGFβ-2 Transforming growth factor-beta 2 Bone formation MS/WB
BMP-3 Bone Morphogenetic Protein 3 Bone formation MS/WB
BMP-2 Bone Morphogenetic Protein 2 Bone formation ELISA, MS/WB
BMP-7 Bone Morphogenetic Protein 7 Bone formation ELISA, MS/WB
IGF-1 insuline-like growth factor 1 Bone formation ELISA
pus, femur, tibia, ﬁbula, metatarsus). Only the compacta of the diaphysis of these bones
was processed. To prepare COLLOSS R©E, cortical diaphyses of equine long bones were ob-
tained from a slaughter house and were cleaned for soft tissue and marrow. Cleaned bones
were pulverised and acetone was used for delipidation (three treatments for 60 minutes at
2 to 7◦C). Following the delipidation, the pulverized cleaned bone was demineralised in
0.6N hydrochloric acid (four treatments for 60 minutes at 3 to 10◦C). The particles were
washed afterwards in water for injection, followed by extraction using a solution of 4M
guanidine hydrochloride buﬀered with trishydroxymethylaminomethane (TRIS), ethylenedi-
aminetetraacetic acid (EDTA) and Hydrogen Chloride solution (HCL), PH 6.9, at 15 to
20◦C for 12.5 hours (two treatments) and 250 minutes (postextraction treatment). The
extracted proteins were puriﬁed using a 3k nominal molecular weight cut oﬀ ultra ﬁlter.
Subsequently, a lyophilization step was performed. The lyophilizate was a collagenous ma-
trix, consisting of Type I collagen chains with other insoluble proteins present. All processing
was performed under aseptic non-pyrogenic conditions. Finally, for the analysis the following
growth factors were examined as stated in Table 3.1.
COLLOSS R©E material was solubilised by putting dry material on top of phosphate buﬀered
saline (PBS) solution. After hydration of the dry material, the PBS was vortexed until a
well-dispersed suspension was obtained.
3.2.2 ELISA
No commercial ELISA kits were available for equine growth factors, but since the amino
acid sequences of human and equine growth factors could share high degrees of sequence
similarity immunological interspecies cross reactivity was expected. Thus, ELISA kits (R&D
Systems, Minneapolis, USA) directed against human- BMP-2, BMP-7, TGF-β1, IGF-1,
VEGF, and bFGF were used to screen three diﬀerent batches of COLLOSS R©E.
3.2.3 Mass spectrometry
The presence of growth factors was also investigated in COLLOSS R©E by mass spectrometry
methods using capillary liquid chromatography – tandem mass spectrometry (LC-MS/MS)5.
COLLOSS R©E was solubilized in PBS and the proteins separated by SDS-PAGE on minigels.
Protein bands in the 10 kDa to 50 kDa range were cut out and in-gel digested with trypsin.
LC-ESI-MS/MS analysis of the peptide samples were performed applying data-dependent
acquisition using the Ultimate 3000 nanoﬂow HPLC system (LC Packings, Amsterdam, The
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Netherlands) in front of a Q-TOF Micro tandem mass spectrometer (Waters, Manchester,
UK). The peptides were separated on a C18 column by a linear gradient of acetonitrile
with 0.5% acetic acid. Peptides were eluted directly into the ESI source, and the mass
spectrometer was operated in positive ion mode. Mass- and charge-dependent collision
energies were used for peptide fragmentation. Proteins were identiﬁed by sequence database
searching (SwissProt Protein Database, Swiss Institute of Bioinformatics) using an in-house
MASCOT server (ver. 2.1) (Matrix sciences, London, UK).
3.2.4 Western blotting
Western Blotting was used for validation of the MS data. In addition to the identiﬁed TGF-
β1, TGF-β2 and BMP-3, two additional growth factors (BMP-2 and BMP-7) were analyzed.
The recombinant human versions of the ﬁve mature growth factor proteins were used as
positive controls. Lyophilized COLLOSS R©E samples were solubilised in PBS. Then 50 μg of
bone extract samples, and 50 ng of each recombinant protein, were loaded per lane on SDS-
PAGE minigels along with molecular weight (MW) markers (PageRuler
TM
, Fermentas Life
Sciences, ON, Canada; and Cruz Marker
TM
protein ladder, Santa Cruz Biotechnology, Inc.,
CA, USA). After electrophoresis, the gels were either stained by colloidal coomassic blue
(CCB) or silver nitrate, or blotted onto Polyvinylidene Fluoride (PVDF) membranes. After
the transfer of proteins form SDS-PAGE gel onto the PVDF membrane, the membranes
were blocked and incubated with primary antibodies (rabbit- or goat-Ab) and secondary
HRP conjugated antibodies (donkey anti-rabbit-Ab or donkey anti-goat-Ab).
3.2.5 Cell culture experiment
Based on the analytical data, it was chosen to compare the eﬀect of COLLOSS R©E in a cell
culture model for bone regeneration, to the eﬀects of BMP-2 and TGF-β1.
Rat bone marrow (RBM) cells were isolated from the femora of a 43 day old male Wistar
WU rat. The femora were washed three times in alpha Minimal Essential Medium (α-
MEM; Gibco BRL, Life Technologies B.V. Breda, The Netherlands) supplemented with
0.5 mg/mL gentamycin (Gibco) and 3 μg/mL fungizone (Gibco). The epiphyses were cut
oﬀ and the diaphyses ﬂushed out with 15 mL culture medium (α-MEM supplemented with
10% fetal calf serum (FCS; Gibco), 50 μg/mL gentamycin, 50 μg/mL ascorbic acid (Sigma,
Chemical Co., St. Louis, MO, USA)), 10 mM Na-β-glycerophosphate Sigma and 10−8M
dexamethasone (Sigma). To obtain osteoblast-like cells, the RBM suspension was divided
over three 75cm2 culture ﬂasks, and incubated in a humidiﬁed atmosphere of 95% air, 5%
CO2 at 37
◦C. After 7 days of primary culture, cells were detached using trypsin/EDTA
(0.25% (w/v) trypsin / 0.02% EDTA), resuspended and seeded at 10.000 cells/cm2 onto
24-well plates (Greiner, Bio-One, Alphen aan den Rijn, The Netherlands). After 4 hours,
the culture medium was replaced with fresh culture medium with added growth factors.
The concentrations of TGF-β1, BMP-2 and COLLOSS R©E were respectively 5.0 ng/mL,
100 ng/mL and 10 μg/mL.
To analyse cell proliferation, after 1, 4, 7, 16 and 24 days of culture, total DNA content was
determined (n=3) using the PicoGreen dsDNS Quantation Kit (Molecular Probes, Leiden,
The Netherlands), according to the manufacturers instruction. The alkaline phophatase
(ALP) activity was measured in the same samples. For the assay, 80 μL of sample and 20
μL of buﬀer solution (5 mM MgCl2, 0.5M 2-amino-2methyl-1-propanol; Sigma) were added
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Table 3.2: Amount of diﬀerent osteoinductive factors in COLLOSS R©E compared to de-
mineralized bone matrix (DBM).
Factor
Amount in 40 mg COLLOSS R©E (ng) Amount in DBM
I (n=3) II (n=3) III (n=7) (ng/cm3)a 19
BMP-2 164.8 ± 52.7 109.0 ± 7.4 103.2 ± 7.5 18.0 ± 7.6
BMP-7 48.0 ± 10.0 39.7 ± 16.9 151.4 ± 107.3 55.3 ± 14.7
TGF-β1 1544.7 ± 538.9 2086 ± 728.2 2200.8 ± 437.8 99.0 ± 40.7
IGF-1 127.3 ± 20.7 93.6 ± 38.0 115.3 ± 31.1 358.0 ± 115.0
aone cm3 of DBM is approximated to be 1 gram
to 96-well plates. Subsequently, 100 μL of substrate solution (5 mM paranitrophenylphos-
phate; Sigma) was added and the plate was incubated for one hour. The reaction was
stopped by the addition of 100 μL 0.3M NaOH and ﬁnally, the plate was read at 405 nm.
With the aid of a standard curve (4-nitrophenol (4-NP); Sigma) serial dilutions ranging
from 0 to 25 nM) the ALP activity was determined in nmol 4-NP produced per hour per ng
DNA. To obtain information about mineralization of the extracellular matrix the cells had
produced, the calcium (Ca) content was determined using the ortho-cresolphtalein complex-
one (OCPC; Sigma) method. The 24-well plates from after DNA and ALP measurement
were rinsed and 500 μL acetic acid 0.5N was added. To prepare the sample solution, 5
mL of OCPC solution was added to 5 mL 14.8M ethanolamine-boric acid buﬀer (pH 11), 2
mL of 8-hydroxyquinoline (5 g in 100 mL 95% ethanol) and 88 mL of demineralised water.
Three hundred μL of this sample solution was then added to 10 μL of sample. The plate
was incubated at room temperature for 10 minutes and read at 575 nm using a microplate
reader. A standard curve was made from serial dilutions of CaCl2 ranging from 1 to 200
μg/mL.
In all tests, samples were present in threefold and measured in duplicate. Statistical analysis
was performed using an ANOVA with post-hoc Turkey test. Calculations were performed
in InStat software (v 3.05 Graphpad).
3.3 Results
3.3.1 ELISA detection
BMP-2, BMP-7, TGF-β1 and IGF-1 were all found in COLLOSS R©E suspension. The
highest amount was seen for TGF-β1, of which 40 mg COLLOSS R©E contained maximally
approximately 2.2 μg. BMP-2 and -7 were detected in equal amounts, although the exact
content diﬀered in the three runs of the experiment (Table 3.2). Traces of VEGF could also
be detected however at a considerably lower level of 9 pg/mg. Finally, bFGF could not be
detected with the ELISA method.
3.3.2 MS and Western Blot analysis
TGF-β1, TGF-β2 and BMP-3 were unambiguously identiﬁed in COLLOSS R©E by mass
spectrometry. Validation of these results with Western Blotting identiﬁed TGF-β1 and TGF-
β2 but not BMP-3 in COLLOSS R©E. BMP-2 or BMP-7 were not identiﬁed in COLLOSS R©E
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Table 3.3: Detection of growth factors in COLLOSS R©E by mass spectrometry and Western
blotting (+ = detected; - = not detected )
Protein
COLLOSS R©E Positive control
MS WB WB
TGF-β1 + + +
TGF-β2 + + +
BMP-3 + - +
BMP-2 - - +
BMP-7 - - +
by mass spectrometry or Western Blotting. For all ﬁve bone morphogenetic proteins the
positive controls were recognized by the antibodies at the expected MW 12.5-12.8 kDa, in
the COLLOSS R©E material (Table 3.3).
3.3.3 Cell culture experiment
The results from the proliferation test on basis of a total DNA measurement are shown in
Figure 3.1A. The control group without any addition gave an increase in DNA content until
day 16. After day 16, a decrease in DNA content was observed. A similar growth pattern
like the control group was seen for all other groups. However, cell proliferation was lower in
the TGF-β1 and COLLOSS R©E groups. These two reached maximum values at the earlier
day 7 time point. At day 16 and 24, DNA values for these groups were signiﬁcantly lower
as compared to the control group. In contrast the BMP-2 group showed a peak value at
day 16, DNA values measured were signiﬁcantly higher than controls at days 7, 16, and 24.
Results of the ALP activity measurement (Figure 3.1B) in the control group showed an
increase in activity in time with a peak value at day 7. In contrast, a signiﬁcant up-
regulation of ALP activity with a maximum around day 16, was observed for the TGF-β1
and COLLOSS R©E groups. Especially the COLLOSS R©E showed signiﬁcantly higher values
as compared to any other group at day 16. The BMP-2 group showed the same patterns
as the control group, while at day 7 the ALP activity was even signiﬁcantly lower.
The calcium measurement (Figure 3.1C) showed that the concentration in the control
groups started to increase signiﬁcantly from day 16 to day 24. The results for TGF-β1 and
COLLOSS R©E showed similar data, with a signiﬁcantly lower calcium concentration at day
16 and 24. In contrast, the values for the BMP-2 group were signiﬁcantly higher than those
for TGF-β1 and COLLOSS R©E, albeit not higher than the controls at day 24.
3.4 Discussion
The current study was performed to identify the diﬀerent growth factors in COLLOSS R©E
by ELISA tests, mass spectrometry/Western blotting, and cell culture experiments. It was
shown that COLLOSS R©E contains at least the growth factors TGF-β1, TGF-β2, BMP-2,
BMP-3, BMP-7, and IGF-1. COLLOSS R©E contained mostly TGF-β1, which explains the
similar eﬀects of COLLOSS R©E and TGF-β1 in the cell culture experiments.
There are several comments to be made about the study set up. First, it was a drawback
that not all techniques could be applied to all growth factors we initially aimed to investigate,
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Figure 3.1: Results of the cell culture experiment. (A) proliferation data based on total
DNA measurement. (B) Alkaline phosphatase activity. (C) Calcium concentration after
dissolving the extracellular matrix. White bar is TGF-β1; light grey is BMP-2, dark grey is
COLLOSS R©E, black is control group. Data show average and standard deviation.
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which was most evident in our measurements for bFGF and VEGF. bFGF and VEGF play an
important role in the process of angiogenesis. The re-establishment of vascularity is an early
event in fracture healing and up-regulation of angiogenesis will promote the formation of
bone13,3. The ELISA method relies on the availability of primary antibodies against (or cross
reacting with) proteins from an equine source. In our experiments, however, bFGF was not
detected, whereas VEGF was found in pg quantities at the detection limit of the method.
These proteins could, of course, be present in very low concentrations, but more likely they
could not be detected with ELISA, because of species homology diﬀerences. Starting our
study we assumed that human ELISA kits would be applicable for the equine material, as
we expected a high degree of sequence similarity. Ideally, comparing sequence data from
human and equine proteins could conﬁrm this, but unfortunately there are no sequences or
other literature data available for equine material. In contrast, all our measurements for
BMP-2, -7, and TGF-β1 are in the expected range of 1-100 ng/mg also described in for
instance bovine and human DBM materials, so in these instances cross reactivity seems
credible. Still, we have to be cautious and underline that the quantitative nature of all data
is also dependent on the interspecies cross-reactivity of the ELISA tests.
Another drawback was that the ELISA and mass spectrometry data did not show the
same results noticeably for the measurements of BMP-2 and BMP-7. Considering the high
levels in the quantitative testing, we can only attribute this to a technical error in the MS
experiment and assume that the ELISA testing was the most accurate for the purpose of
this study. Yet, mass spectrometry detected successfully BMP-3, TGF-β1 and TGF-β2. A
multitude of other growth factors was found to be present, but could not be identiﬁed as
such, due to inherent detection limits of the used ELISA and mass spectrometry techniques.
BMP-3 was identiﬁed by mass spectrometry, but not in Western Blotting, although the
polyclonal primary antibodies recognized the positive control consisting of rhBMP-3. In
short, alternative proteomics methods might be necessary to conﬁrm the results presented
and also to detect other growth factors.
It seems logical to compare data from our COLLOSS R©E analysis to the existing knowledge
about demineralised bone matrix (Table 3.2). Blum et al. measured BMP-2, -4, TGF-β1
and IGF-1 in demineralised bone matrix. A strong association was found between BMP-2
and TGF-β1 levels2. Woodell-May et al. quantiﬁed a broad growth factor proﬁle from
DBM. They described that DBM contained BMP-2, -4, and –7, IGF-1, TGF-β1, VEGF,
PDGF-BB, EGF and FGF-219. Pietrzak et al. measured levels of BMP-2, -4, and – 7 in
DBM by ELISA. They found a positive linear correlation between BMP-2 and –712. The
COLLOSS R©E material studied here, however, consistently contained higher levels of the
bone promoting factors, compared to data found on DBM.
The detected growth factors can explain the behaviour of COLLOSS R©E in the present in
vitro experiments. The cell culture, as well as the ELISA measurements showed that TGF-
β1 is the main growth factor in COLLOSS R©E. In our cell culture experiment it was evident
that COLLOSS R©E was almost perfectly homologous to TGF-β1, even though calculations
show that in the 10 μg/mL COLLOSS R©E used, only approximately 0.5 ng/mL TGF-β1
was present, whereas in the TGF-β1 added group 5.0 ng/mL was used. The eﬀects of
BMP in COLLOSS R©E in cell culture are apparently overruled by the eﬀects of TGF-β1,
but the other growth factors can enhance the eﬀect of TGF-β1 alone. Similar results
have been reported by other authors18,4,21. Woo et al. demonstrated signiﬁcant metabolic
eﬀects of bovine COLLOSS R© on (human) mesenchymal stem cells. Van der Zande et al.
concluded that the observed eﬀects of COLLOSS R©E mainly resembled those of TGF-β1
39
application alone. Similar results to our culture data are seen in the literature, as Woo et
al. demonstrated signiﬁcant metabolic eﬀects of a bone morphogenetic protein from bovine
source (COLLOSS R©) on (human) mesenchymal stem cells18. El-Sabban et al. concluded
that both COLLOSS R© and COLLOSS R©E induced osteoblastic diﬀerentiation of in vitro
expanded bone marrow-derived mesenchymal stem cells4. Van der Zande et al. concluded
that the observed eﬀects of COLLOSS R©E mainly resembled those of TGF-β121.
The detected growth factors can also explain the behaviour of COLLOSS R©E in previously
described in vivo rat studies16,6,8,17,11. The enhancement of bone regeneration by topical
application of growth factors appears to be best achieved by BMPs14. TGF-β1 and BMPs
are osteopromotive in bony defects, however, only the BMPs are osteoinductive, when
tested in ectopic defect sites. The multitude of osteoinductive factors in COLLOSS R©E, in
elevated quantity compared to DBM, induces a wide physiological spectrum of signalling
cascades, leading eventually to new bone formation. This is especially in contrast to com-
mercially available single content rhBMPs such as OP-1 R© (Stryker, MI, USA) or INFUSE R©
(Medtronic, MN, USA). It is remarkable that the bone formation induced by COLLOSS R©E
is apparently largely dependent on the synergistic eﬀects of all growth factors present com-
bined. This process also requires a much lower BMP content to achieve bone formation,
as compared to tissue engineering strategies, using the addition of a single recombinant
protein.
Still, we have to acknowledge that the exact eﬀects of the TGF-β superfamily (including
TGF-β1 and the BMPs) on bone formation, diﬀerentiation, and resorbtion are extremely
complicated. For example, while TGF-β1 is known to induce migration and diﬀerentiation
of osteoblasts, it inhibits mineralization. Thus while it is likely that TGF-β and BMP-
2 are responsible for much of the bone formation capacity of COLLOSS R©E, this claim
would be dramatically strengthened when more literature data becomes available relating
to all (lesser present) growth factors found in COLLOSS R©E. Moreover future work should
elucidate interaction between growth factors in such a complex (bio mimetic) growth factor
mixture, a process which thus far is poorly understood.
3.5 Conclusion
COLLOSS R©E is not only a rich source of TGF-β1, but also contains the growth factors
TGF-β2, BMP-2, BMP-3, BMP-7, IGF-1 and possibly VEGF. Other growth factors might
be present in COLLOSS R©E, but were not identiﬁed in these experiments, due to inherent
detection limits of the used ELISA and mass spectrometric techniques. Alternative methods
should be explored to conﬁrm if more bone promoting proteins are present. The multitude
of osteoinductive factors in COLLOSS R©E, caused a proliferative eﬀect on osteoblast-like
cells in culture, with a behaviour conﬁrming the relatively high TGF-β1 content. The
combined activity and synergistic eﬀects of a wide array of growth factors may induce a
wide physiological spectrum of signalling cascades, explaining the found new bone formation
in previously described in vivo studies, with much lower BMP concentrations present as
compared to tissue engineering strategies using recombinant BMPs.
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Bone-like tissue formation using an equine COLLOSS R©E-ﬁlled titanium scaﬀolding
material
4.1 Introduction
The use of autogenous bonegrafts in reconstructive surgery is still considered to be the gold
standard2,3,5. There is, however, a general interest for bone substitutes to diminish or even
overcome the need for bone harvests. Donor site morbidity, limited availability and the need
for a second operation site, are among the factors that press for such a drive. Aside from the
search for bone substitutes such as allografts, alloplasts and xenografts, there is a growing
interest in tissue engineering (TE). Researchers have tried to produce biologically active,
i.e. cell- and/or growth factor loaded, scaﬀolds8. These osteoinductive constructs tend to
produce new bone, which can be used to bridge bony defects. In TE approaches, especially
bone morphogenetic proteins (BMPs) have proven to possess potential for enhancing bone
formation. BMPs, however, are only eﬀective in high physiological concentrations.14,16,15.
Unfortunately, recombinant BMPs are not readily available and very expensive, which limits
their clinical use and justiﬁes the search for cost-eﬀective alternatives.
COLLOSS R©, a lyophilized complex of the extracellular matrix proteins extracted from dia-
physeal bovine bone, containing native BMPs, has proven to be eﬀective in enhancing bone
formation. In previous animal studies, COLLOSS R© has been used to enhance osseointegra-
tion of implants13, to investigate its osteoinductive potential when compared to autogenous
bone7 and to coat hydroxyapatite implants4. All authors concluded that COLLOSS R© stim-
ulated bone formation. In these studies, only orthotopic implant sites were used. To inves-
tigate the bone-inductive potential of COLLOSS R©, Walboomers et al.17 used an ectopic
implant site and showed that COLLOSS R© indeed induced the formation of bone.
COLLOSS R©, however, is derived from bovine sources. Clinical application of such bovine
materials in humans is a continuous issue of discussion, because of the risk of Transmissable
Spongiform Encephalopathy (TSE) infection. To overcome this problem, recently a similar
equine material was prepared, COLLOSS R©E1. There is no TSE known in horses in the
reports of the Oﬃce International des Epizooties. TSE is only known as diﬀerent infectious
disease in bovines, sheep, goats, cervids, farmed mink, domestic cats and exotic ungulates
in zoos9,18.
The aim of this study is to investigate this equine-derived material for osteoinductive pro-
perties in the same ectopic rat model as used before17. In this study various types of
titanium mesh ﬁbre scaﬀolds were loaded with COLLOSS R©E. These were assessed in an
ectopic rat model in order to investigate the eﬃcacy of the equine material. The hypothesis
was that COLLOSS R©E is osteoinductive and that bone will be formed inside the titanium
scaﬀolds.
4.2 Material and Methods
4.2.1 Implants
Titanium ﬁbre mesh sheets (Bekaert, Zwevegem, Belgium) were used to manufacture two
types of implants. The used titanium ﬁbre mesh had a ﬁbre-diameter of 45 μm and a 86%
volumetric porosity. First, tube-shaped implants were made with a length of 10 mm, a 3
mm inner and a 5 mm outer diameter. Second, disc-shaped implants were made with a
diameter of 6 mm and 1 mm thickness.
The manufacturer (OSSACUR AG, Oberstenfeld, Germany) extracts COLLOSS R©E material
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Figure 4.1: (A) Tube shaped implant, loaded with COLLOSS R©E. Titanium mesh ﬁbre
material was used to make a cylinder of 1 cm length, 3 mm inner and 5 mm outer diameter.
The central space of the cylinder was ﬁlled with 20 mg of dry COLLOSS R©E material. (B)
Disc shaped implant, loaded with COLLOSS R©E. Titanium mesh ﬁbre material was used to
make a disc with a diameter of 6 mm and one 1 mm in thickness. The porous disc was
saturated with soluted COLLOSS R©E material and lyophilized afterwards.
from the extracellular matrix of equine long bone (i.e. humerus, radius, metacarpus, femur,
tibia, ﬁbula, metatarsus) of foals younger than 12 months of age. Only the compacta of the
diaphysis of these bones are processed. The lyophilizate is a collagenous matrix, consisting
of Type I collagen chains with other insoluble proteins, amongst others the growth factors
BMP-2 and and transforming growth factor-β1 (TGF-β1). The precise contents of the
COLLOSS R©E mixture, however, have not been fully determined. All processing is performed
under aseptic conditions.
The central space of the tubes was ﬁlled with 20 mg dry COLLOSS R©E. The porous disc
implants were placed in 2 ml saline solution in which COLLOSS R©E was dissolved. Samples
were frozen at -20◦C and lyophilized afterwards. In total 40 mg dry equine material for 18
discs. No material was left over after lyophilization, thus resulting in a loaded amount of
2.2 mg per disc. The implant designs are shown in Figure 4.1. Empty tubes and discs (i.e.
without COLLOSS R©E material) were always used as controls.
4.2.2 Animal model and implantation procedure
For this implantation study, 18 healthy young Wistar rats (40-43 days) were used. Approval
was obtained from the Radboud University Nijmegen Animal Ethics Committee (KUNDEC
2004-116) and the national guidelines for the care and use of laboratory animals were obeyed.
Surgery was performed under general anaesthesia (isoﬂurane 1,5-3 %). The back of the
animals was shaved; the skin was washed and disinfected with povidone-iodine. On each
ﬂank, parallel to the spinal column, two small incisions of about 5 mm were made through
the skin. Using blunt dissection, subcutaneous pockets were created. Thereafter, one of
each implant type was positioned in the pockets (i.e. four implants per animal, one loaded
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Table 4.1: The diﬀerent implants types used in this study
Implant Time (weeks) n Total Implants
Ti tubes without COLLOSS R©E 2, 8, 12 6 18
Ti tubes with COLLOSS R©E 2, 8, 12 6 18
Ti discs without COLLOSS R©E 2, 8, 12 6 18
Ti discs with COLLOSS R©E 2, 8, 12 6 18
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tube, one control tube, one loaded disc and one control disc, Table 4.1). The incisions were
closed with staples.
4.2.3 Histological procedures
After implant periods of 2, 8 and 12 weeks, the animals were sacriﬁced and the tissue-
covered implants were retrieved. The implants were ﬁxed in 4% buﬀered formaldehyde
for one week, dehydrated in a series of ethanol water solutions, and embedded in methyl
methacrylate (MMA). After polymerization, 10 tot 15 μm sections of all implants were cut
in a longitudinal direction, using a modiﬁed diamond blade sawing technique. Sections were
stained with methylene blue and basic fuchsin11. At least three sections of each sample were
used for evaluation. All longitudinal sections were obtained at the centre of the implant.
4.2.4 Histomorphometry
All histological sections were digitally photographed and histomorphometrically evaluated
by a blinded observer. First, the number of positive implants (i.e. implants showing the
presence of bone) was determined. Subsequently, areas of new-formed bone tissue were
selected and the total area occupied by bone was measured (in mm2) using image analysis
software (Scion Image Beta 4.02 Win, Frederick, MD, USA). Finally, average values were
calculated.
4.2.5 Statistical analysis
Statistical analysis was performed using GraphPad Instat (v3.05, GraphPad Software, San
Diego, CA, USA) using a Students t-test and a Chi-square test.
4.3 Results
4.3.1 Macroscopic ﬁndings
One animal in the two weeks group died, whilst administering general anaesthesia for the
operation. The other rats appeared to be in good health throughout the test period.
There were no signs or symptoms of inﬂammation at the implantation sites. At sacriﬁce,
all implants could easily be detected by palpation and retrieved with the surrounding soft
tissues.
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4.3.2 Descriptive histological evaluation
4.3.2.1 Disc implants, two weeks
At two weeks, none of the histological sections showed any bone formation. A thin layer of
ﬁbroblasts surrounded the outer perimeter of the non-loaded titanium ﬁbre meshes. This
layer was almost free from inﬂammatory cells in all cases. When regarding the interstitial tis-
sue, no chronic toxic tissue response to the titanium ﬁbre mesh was seen. The mesh porosity
was ﬁlled with immature connective tissue. Occasionally, blood vessels, and scattered foci
of macrophages or other inﬂammatory cells were observed (Figure 4.2A).
The histological aspect of the loaded samples was very similar to the non-loaded specimens
in terms of ﬁbrous tissue encapsulation and connective tissue formation in the mesh inter-
stitium was similar. However, in this group all samples showed abundant inﬁltration with
inﬂammatory cells (Figure 4.2B).
4.3.2.2 Disc implants, eight weeks
At eight weeks, none of the sections showed any bone formation. In both loaded and non-
loaded samples, the connective tissue in the interstitial space and capsule was matured.
Compared to the loaded two-weeks samples, the inﬂammatory reaction had decreased sig-
niﬁcantly.
4.3.2.3 Disc implants, 12 weeks
In the 12 weeks samples, still no bone formation was found. No apparent diﬀerences between
loaded en non-loaded discs were seen; the tissue response towards the titanium mesh disc
was characterized by a matured interstitial connective tissue and a thin ﬁbrous encapsulation
(Figure 4.2C) .
4.3.2.4 Tube implants, two weeks
The two-weeks histological sections showed that a thin layer of ﬁbroblasts surrounded the
outer perimeter of non-loaded titanium ﬁbre mesh tubes. This connective tissue was gener-
ally free from inﬂammatory cells. Examination of the tissue within the ﬁbre mesh, revealed
that pores where ﬁlled with immature connective tissue. Noticeably, the central space of
the tubes was still devoid of any connective tissue ingrowth.
The loaded samples showed similar mild capsule formation as the controls. However, as
compared to the non-loaded two-week tubes, the connective tissue had grown halfway into
the central space of the tube. Upon close inspection at higher magniﬁcation, small areas of
mineralized tissue were seen within the titanium mesh in 60% of the sections (Figure 4.3).
The mineralized tissue had the characteristics of early stage bone formation.
4.3.2.5 Tube implants, eight weeks
The sections of the non-loaded samples showed that a thin and mature ﬁbrous tissue capsule
was present around all implants. The thin ﬁbrous capsule closely followed the perimeter
of the outer titanium ﬁbres (Figure 4.4A). Connective tissue ingrowth into the interstitial
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Figure 4.2: (A) Light micrograph of histology of a non-loaded disc after 2 weeks of im-
plantation Note the thin ﬁbrous tissue capsule (methylene blue and basic fuchsin stain
magniﬁcation 2,5x). (B) Light micrograph of histology of a COLLOSS R©E –loaded disc
after 2 weeks of implantation. Note the inﬁltration with inﬂammatory cells (methylene
blue and basic fuchsin stain magniﬁcation 10x). (C) Light micrograph of histology of a
COLLOSS R©E –loaded disc after 12 weeks of implantation. Note the ingrowth of soft tissue
(methylene blue and basic fuchsin stain magniﬁcation 1,6x).
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Figure 4.3: Light micrograph of histology of a COLLOSS R©E-loaded tube after 2 weeks of
implantation, showing bone-like tissue (methylene blue and basic fuchsin stain magniﬁcation
20x).
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Figure 4.4: (A) Light micrograph of histology of a non-loaded tube after 8 weeks of im-
plantation. Note the ﬁbrous capsule closely following the perimeter of the outer titanium
ﬁbres (methylene blue and basic fuchsin stain magniﬁcation 10x). (B) Light micrograph of
histology of a non-loaded tube after 8 weeks of implantation. Note the thin ﬁbrous tissue
capsule (methylene blue and basic fuchsin stain magniﬁcation 1,6x).
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Table 4.2: The number of positive tube implants, i.e. implants in which bone-like tissue
was observed.
Time Control Implant COLLOSS R©E
(weeks) Implant
No. of positives No. of positives
2 0/5 3/5
8 0/6 3/6
12 0/6 6/6
porosity of the mesh, and the central space of the tube had progressed more in comparison
to the two-weeks specimens. Still, a large part of the central space of the tubes was not
ﬁlled with connective tissue yet (Figure 4.4B).
For the COLLOSS R©E loaded tube-shaped implants, the perimeter of the titanium mesh
was also surrounded by a ﬁbrous capsule. The interstitium between the ﬁbres as well as
the central space in the tube contained immature loosely organized connective tissue and
seemed to contain loose ﬁbres as well as patches of the the COLLOSS R©E material. Small
areas of newly formed bone, as characterized by the presence of osteocytes in a mineralized
matrix, were seen in 50% of the sections examined (Figure 4.5A and 4.5B). Often the newly
formed bone tissue was adjacent to the titanium material, but occasionally titanium mesh
ﬁbres were even incorporated in the newly formed bone tissue.
4.3.2.6 Tube implants, 12 weeks
Histology of the non-loaded specimens showed great similarity to the eight week specimens.
A large part of the central tube space was still not occupied by connective tissue. In overview,
also the tissue response to the COLLOSS R©E-loaded samples showed great resemblance to
the 8 week situation. However, at 12 weeks all loaded specimens showed areas of bone
tissue formation (Figure 4.6A).
The bone tissue was characterized by the presence of osteoblasts, and osteocytes embedded
in a calciﬁed extracellular matrix. Within this tissue, usually a bone marrow-like tissue could
be observed. The bone marrow-like tissue was characterized by the presence of fatty tissue
and abundant haematopoietic cells (Figure 4.6B). The newly formed bone tissue was again
mostly adjacent to the titanium material. However, also some separate islands of bone
tissue inside the central tube space could occasionally be observed.
4.3.2.7 Histomorphometric evaluation
The number of implants showing formation of bone tissue is listed in Table 4.2. After two
weeks of implantation, in three out of ﬁve loaded implants, bone was observed. After eight
weeks, three out of six loaded implants showed bone. The Chi-square test showed that
the number of positive implants could not be regarded as statistically signiﬁcantly diﬀerent
between the loaded and non-loaded tubes. After 12 weeks of implantation, however, all
loaded tubes showed bone formation. Statistical testing (Chi-square) revealed that this
diﬀerence is signiﬁcant as compared to the control situation.
Figure 4.7 shows the histomorphometric results of the area measurements for the formation
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Figure 4.5: (A) Light micrograph of histology of a COLLOSS R©E-loaded tube after 8 weeks
of implantation. Note the bone formation adjacent to the titanium material (methylene
blue and basic fuchsin stain magniﬁcation 1,6x). (B) Detail of A (10x).
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Figure 4.6: (A) Light micrograph of histology of a COLLOSS R©E-loaded tube after 12 weeks
of implantation. Note the formed bone-like tissue (methylene blue and basic fuchsin stain
magniﬁcation 1,6x). (B) Detail of A (10x). Note the incorporation of titanium mesh ﬁbres
in the newly formed bone and the presence of fatty tissue.
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Figure 4.7: Result of the histomorphometric analyses measurements of bone area. The
amount of new bone is presented in mm2.
of bone-like tissue in mm2. Statistical testing, using a students t-test, showed only a
signiﬁcant diﬀerence between the total areas of bone formation between two and twelve
weeks (p = 0,037), where no diﬀerence was observed between two and eight and between
eight and 12 weeks.
4.3.2.8 Discussion
The aim of the study was to investigate the osteoinductive properties of COLLOSS R©E
material. Loaded versus non-loaded (control) titanium ﬁbre mesh implants of two diﬀerent
types were implanted ectopically in rats. It was proven that COLLOSS R©E material was
osteoinductive in tube-shaped titanium mesh implants.
Histological analysis revealed a mild tissue response to all types of implants and favourable
performance of the titanium mesh ﬁbre. The titanium mesh appeared to be an easy to
handle material, which combines porosity with malleability. This is in agreement with the
results of previous studies using this material12. The implantation of COLLOSS R©E titanium
implants evoked an initial inﬂammatory response, which however receded after eight weeks
of implantation. The latter could be regarded a typical response with regards to the animal
model and ectopic (soft tissue) implantation site.
The titanium mesh disc model was previously used to study bone formation induced by
combined applications of calcium phosphate coatings, bone marrow strolal cells and re-
combinant growth factors like BMP-2 and TGF-β114,15,16,6. Still, in the current study the
disc-shaped implant design, loaded or non-loaded, did not reveal any sign of new bone
formation. The porosity of the titanium ﬁbre mesh should not be a factor as it did not
diﬀer between the tube and disc implants. Therefore, we suppose that this is due to the
application mode of the COLLOSS R©E material. In the tube-shaped implants, dry material
was inserted, while in the disc-shaped implants re-dissolved and subsequently lyophilized
COLLOSS R©E was used. Also, the relative amounts of loaded COLLOSS R©E was diﬀerent
between the two scaﬀolds. When describing the amounts of COLLOSS R©E as weight per
volume, it can be calculated that there was a 3-fold lower concentration within the porosity
of the disc-shaped meshes, as compared to the amount loaded in the central space of the
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tubes. Apparently, application form and/or amount of material are decisive parameters for
ﬁnal bone induction.
In contrast to the discs, in the tube-sized loaded implants in an ectopic location, bone tissue
was observed, after two, eight, and twelve weeks with increased frequency, which implies
that the equine material has osteoinductive properties. The overall results of this study
are comparable with the results of a previous study on bovine material17. The maximal
amount of bone tissue found in the current study was 1,04 mm2 versus 1,17 mm2 with the
bovine-derived COLLOSS R© study. The amount of formed bone is still low, as 1,04 mm2 on
a 10 x 3mm area is less than 5% of total bone ﬁll area in the construct. It is well possible
that upon contact with tissue ﬂuids, the material will shrink considerably. Also, placing the
material in the central space of the tube scaﬀold can be a reason for the low ﬁlling capacity
observed17. Placing COLLOSS R©E within the porosity of an osteoconductive scaﬀold for
the future seems more appropriate, to achieve higher ﬁlling percentages.
Diﬀerences in tissue reaction between loaded and non-loaded samples were, beside the
formation of bone, also seen. Loaded samples showed faster ingrowth of connective tissue
and more inﬂammatory reaction, as compared to non-loaded samples. This is in keeping
with a previous study on the discs17. Further, in the non-loaded tubes the central space
is not completely ﬁlled with connective tissue, even after 12 weeks, while in the loaded
tubes after eight weeks no lumen is left. COLLOSS R©E seems to induce a higher connective
tissue acceleration rate. Of course, a diﬀerent pattern of connective tissue ingrowth was
also seen between the disc and tube shapes. Such diﬀerences in term might also be partially
explanatory for the diﬀerence found in the bone formation amongst both types of scaﬀold.
Currently, only one study17 showed the osteoinductive capacity of bovine COLLOSS R©, using
an ectopic implant site. Comparison of the histological data of the current study with this
bovine study shows that the results are very similar. Only a few studies have shown the
positive inﬂuence of bovine COLLOSS R© on bone formation in orthotopic sites. A study
with bony defects in the frontal bone of pigs showed an acceleration of bone regeneration
in the early phase, as compared to defects ﬁlled with autogenous bone7. After 26 weeks,
however, the results were comparable. Another study in pigs13 showed the inﬂuence on
bone formation in the initial healing phase also when implant beds were conditioned with
COLLOSS R©. This result was, however, not signiﬁcant. Wiltfang et al. demonstrated also an
eﬀect of COLLOSS R© on the early initiation of bony regeneration in orthotopic defects in the
frontal region of mini-pigs19. Further, in a study dealing with uncoated and hydroxylapatite
coated implants4, it was found that the use of additional COLLOSS R© coating promoted
osteogenesis. In spinal fusion experiments COLLOSS R© was also found to be eﬀective as a
bone graft substitute, since it achieved the same fusion rate and the same percentage of
new bone as that of autogenous bone grafts after 12 weeks.10. These results in orthotopic
sites suggest that the osteoinductive properties of COLLOSS R© are mostly prominent in the
early phase of bone formation. The ﬁnal percentage of newly formed bone will approach
the amount of bone when autogenous bone grafts are used.
The observed high connective tissue acceleration rate of COLLOSS R©E, can be attributed to
the presence of collagen Type I. The collagen chains provide a three-dimensional framework
that facilitates in growth of blood vessels and bone forming cells. This tissue conductivity
might also exist in a bone environment. The osteoinduction, however, has to be based on
the extracellular matrix that still contains growth factors, which stimulate mesenchymal cells
to diﬀerentiate into bone-forming cells. The osteopromotive and osteoinductive properties
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are probably depending on the amount and application form of COLLOSS R©E applied.
Future studies are necessary to investigate the relation between amount of COLLOSS R©E
and bone formation. Besides the amount of applied COLLOSS R©E material, also the use of
an osteoconductive scaﬀold could increase the amount of formed bone. For future clinical
application, extrapolation to the human setting is necessary. Therefore, it would be advisable
to further investigate the behaviour of COLLOSS R©E, also at longer implantation times and
in large bone defects in larger animals.
4.4 Conclusion
In conclusion, it was demonstrated that equine COLLOSS R©E material, loaded in a titanium
ﬁbre mesh tube shows osteoinductive properties, similar to COLLOSS R©. It remains to be
seen whether the eﬀect on bone formation is depending on the amount of COLLOSS R©E.
The eﬀect of COLLOSS R©E has to be further investigated, in order to assess the possible
clinical application of COLLOSS R©E for bone reconstruction.
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5.1 Introduction
For bony reconstructions in the maxillofacial area it is common practice to use autoge-
nous bone, sometimes mixed with bone substitutes. This process, however, is known to
have several drawbacks, including donor site morbidity. To overcome this problem, there
is an ongoing interest in engineered bone. Bone tissue engineering techniques involve the
use of a cell or growth factor loaded carrier6. Previous reports from our department have
demonstrated, that for instance titanium ﬁber mesh is suitable to act as a carrier15,16,10. Ti-
tanium is, however, a non-degradable material, whereas for clinical applications a degradable
scaﬀold material sometimes is preferred. Mineralized collagen4 can serve as a degradable
material and has the additional advantage that it is malleable in diﬀerent conﬁgurations and
also maintains its shape after implantation. It has even been suggested that mineralized
collagen promotes the osteogenic diﬀerentiation when studied in cell culture experiments
with human mesenchymal stem cells1.
In addition to a suitable carrier material, osteoinductive morphogenetic proteins are needed
for successful engineering of bone. These proteins predominantly belong to the transform-
ing growth factor beta (TGF)-β superfamily e.g. bone morphogenetic proteins (BMPs).
High concentrations of BMPs are, however, required to generate bone tissue in large ani-
mals and humans17. BMPs are also very expensive, which hampers their clinical use and
justiﬁes the search for equally potent and more cost-eﬀective alternatives. In previous
studies such alternative osteoinductive materials like COLLOSS R© and COLLOSS R©E have
already been suggested10,18. These materials consist of a lyophilized complex of extracellu-
lar matrix proteins extracted from respectively bovine and equine bone. The osteoinductive
properties of these materials can be explained by the presence of transforming growth factor-
β1 (TGF-β1), bone morphogenetic proteins (BMPs) and other associated growth factors9.
After implantation, the obtained histological data conﬁrmed the osteoinductive capacity of
COLLOSS R© and COLLOSS R©E. In these studies, however, the amount of newly formed
bone was limited, reason why a dose-related eﬀect was suggested.
Another explanation for the limited amount of bone found in the above mentioned studies,
was the fact that there was a lack of an osteoconductive material that could facilitate the
ingrowth of bone forming cells. To serve this purpose, especially β-tricalcium-phosphate
(β-TCP) has proved to be suitable8,11,2.
In the current study, a mineralized collagen tube will be used as a dimensionally stable
carrier for COLLOSS R©E7, implanted subcutaneously in rats. The hypothesis of this study
is threefold. First, it is expected that the mineralized collagen will act as a suitable carrier.
Second, more bone will be formed as compared to the previous studies10 18, by increasing
the amount of COLLOSS R©E. Third, the addition of β-TCP and the combination with a
more stable supporting material is expected to facilitate the ingrowth of bone cells and to
increase the amount of newly formed bone.
5.2 Material and Methods
5.2.1 Mineralized collagen
Tubes made of mineralized type I collagen with interconnecting pore structure and elastic
mechanical properties were prepared as described by Lode et al.7. Brieﬂy, non-soluble col-
lagen type I from horse tendon (Colasol 1, S. C. Sticla si Ceramica Poneti SRL, Bucharest,
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Figure 5.1: The tube-shaped implant was made of mineralized collagen and had a length of
10 mm, an outer diameter of 12 mm and an inner diameter of 9 mm. The central space of
the tube was (A) left open to serve as a control, (B) ﬁlled with 40 mg of dry COLLOSS R©E,
or (C) ﬁlled with a mixture of 40 mg of dry COLLOSS R©E and 0.5 cc β-TCP particulate
(OSSAPLAST R©).
Romania) was suspended in diluted hydrochloric acid, mixed with a 0.1 M calcium chloride
solution and then the pH was adjusted to 7.0 by addition of TRIS- and phosphate buﬀer.
Afterwards, the mixture was warmed up to 37◦C for 12 hours. During this time, nanocrys-
talline hydroxyapatite precipitated on the collagen gel. The composite was collected by
centrifugation, poured into suitable tubular moulds (length 40 mm, outer diameter 12 mm
inner diameter 9 mm) and frozen at -20◦C. After freeze drying, the tubes (thickness of the
tube walls about 1.5 mm) were chemically crosslinked with a 1 wt% solution of (1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide Hydrochloride) (EDC) hydrochloride in 80 vol% ethanol
for 1 hour. Finally, the material was washed with water, lyophilized a second time, cutted
to tubes with a length of 10 mm and then sterilized by γ-irradiation. The mineralization
process led to a collagen hydroxyapatite nanocomposite material that had a composition
close to that of the extracellular bone matrix (mineral content of about 60% and collagen
content of 40%).
5.2.2 Implants
Three types of implants were prepared and the implant design is shown in Figure 5.1.
1. Mineralized collagen tubes ﬁlled with 40 mg of dry COLLOSS R©E (Ossacur, Ober-
stenfeld, Germany, batch number I05243).
2. Mineralized collagen tubes ﬁlled with 40 mg dry COLLOSS R©E and 0,5 cc beta-
tricalcium-phosphate (β-TCP) particulate (OSSAPLAST R©, Ossacur, batch number
I05263).
3. Empty mineralized collagen tubes served as a control.
5.2.3 Animal model and implantation procedure
Eighteen healthy young Wistar rats of 40 to 43 days old were used, six in each of the
three groups. The animal numbers were based on a power calculation and experience in
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Figure 5.2: The implantation procedure started with (A) the creation of a subcutaneous
pocket in the back of the animal, parallel to the spinal column, (B) the implant was placed
into the subcutaneous pocket, (C) which was closed with staples afterwards.
Figure 5.3: Postoperatively an inﬂammation reaction was seen macroscopically, i.e. redness
and swelling. The loss of hair could be the result of scratching, that resulted from irritation.
the previous rat study10. Approval was obtained form the Radboud University Nijmegen
Animal Ethics Committee (# DEC2005112) and the national guidelines for the care and
use of laboratory animals were obeyed. Surgery was performed under general Isoﬂurane
inhalation anesthesia. The minimum alveolar concentration (MAC) of Isoﬂurane was ∼
1.25 vol % in order to maintain a chirurgical level of anesthesia in the rats. The back
of the animals was shaved, washed and disinfected with povidone-iodine. Parallel to the
spinal column, one small incision of about 7 mm was made through the skin. Using blunt
dissection a subcutaneous pocket was created. Each animal received one type of implant.
The incisions were closed with staples (Figure 5.2). Animals were observed and weight was
recorded daily during the ﬁrst week postoperatively. No analgesics were administered.
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5.2.4 Micro-computed tomography
The implantation period was 12 weeks after which the animals were euthanized humanely
in a closed chamber, slowly replacing O2 by CO2.
The areas of implantation were excised and the implants, surrounded by soft tissue, were
ﬁxed in 4% buﬀered formalin for two days. Micro-CT images (Skyscan-1172, Skyscan NV,
Aartselaar, Belgium) were subsequently made to analyze the bone morphology and bone
density.
5.2.5 Histological procedure
The specimens were subsequently ﬁxed in 4% buﬀered paraformaldehyde for 72 hours,
dehydrated in a graded series of ethanol and embedded in paraﬃn. Three sections of 6
μm thickness were then cut in a plane parallel to the long axis of the tube, using a Leica
RM 2165 Microtome (Leica Microsystems, Rijswijk, the Netherlands). The sections were
stained with haematoxylin/eosin and at least three sections of each specimen were studied.
5.2.6 Histomorphometry
All histological sections were digitally photographed and histomorphometrically evaluated.
It was planned to determine the number of implants that gave rise to new bone forma-
tion, as well as the total area occupied by bone (in mm2), using image analysis software
(Scion Image Beta 4.02 Win, Frederick, MD, USA). Statistical analysis was planned, using
GraphPad Instat (v3.05, GraphPad Software, San Diego, CA, USA). A Chi-square test was
planned for the rate of bone formation and an ANOVA with post hoc Tukey test for further
quantiﬁcation.
5.3 Results
5.3.1 Macroscopic ﬁndings
The animals appeared to be in good health in the postoperative period. They all had a
normal eating pattern and no weight loss was recorded. All animals showed redness and
swelling of the skin in the areas of implantation, suggesting an inﬂammatory reaction. In ﬁve
animals randomly distributed over all three experimental tubes, this inﬂammatory response
was more severe (Figure 5.3).
After sacriﬁcing the animals, the empty collagen tubes were diﬃcult to locate and could
only be identiﬁed as pigmented stains in the subcutaneous tissue (Figure 5.4A). The colla-
gen tubes ﬁlled with COLLOSS R©E and the COLLOSS R©E/ β-TCP mixture, were hard on
palpation suggesting bony growth (Figure 5.4B). The β-TCP granules were clearly visible
in the subcutaneous tissue (Figure 5.4C).
5.3.2 Micro-computed tomography
The micro-CT images clearly distinguished between radiopaque matter, including bone and
β-TCP granules and radiolucent matter i.e. soft tissue. In the empty controls, no hard
tissue was present at all (Figure 5.5A). All the COLLOSS R©E-ﬁlled collagen tubes showed
68
The evaluation of mineralized collagen as a carrier for the osteoinductive material
COLLOSS R©E, in vivo
radiopaque tissue in the centre of the implant (Figure 5.5B). The β-TCP granules were
clearly visible in the images of tubes ﬁlled with COLLOSS R©E, together with β-TCP (Fig-
ure 5.5C). The images showed, in between the granules, also some radiopaque material.
Newly formed bone-like tissue, β-TCP grains and mineralized collagen all showed similar
radiopacity, precluding further quantitative analysis.
5.3.3 Descriptive histological evaluation
5.3.3.1 Empty mineralized collagen tube
In the explanted tissue, three of the control tubes had resorbed completely. At histological
observation only the normal structures of the skin, subcutaneous and muscle tissues, were
seen. In the explanted tissue of the other three control animals, the contour of the tube
could be recognized, but was completely resorbed and replaced by fatty tissue. The fatty
tissue was surrounded by a ﬁbrous tissue capsule (Figure 5.6A). The capsule at the medial
side was 4-6 cells thick, without signs of inﬂammation. At the dorsal side, the capsule
was 2 to 3 cell layers thicker. Within the fatty tissue two distinct, centrally lying zones
could be recognized. The largest of these zones showed a brown staining, which could
either be the remnants of degrading mineralized collagen or possibly of a hematoma. This
zone was further characterized by the abundant presence of inﬂammatory cells including
macrophages (Figure 5.6B). There was also ample evidence of formation of capillaries. The
other zone showed a honeycomb-like structure, which was stained bright red, suggesting
the remainders of the mineralized collagen. The internal structure of each “cell” of the
honeycomb was ﬁlled with immature connective tissue that was poorly stained. At higher
magniﬁcation many capillaries were seen (Figure 5.6C). The mineralized collagen did not
contain osteoblasts and osteoclasts, neither bone marrow-like tissue or deposits of osteoid.
5.3.3.2 COLLOSS R©E-ﬁlled collagen tubes
In the COLLOSS R©E-ﬁlled collagen specimen, also two distinct types of tissue response
were seen. In the explants of the ﬁrst three animals, a thick layer of immature connective
tissue had formed subcutaneously (Figure 5.6D). Fatty tissue was present, however, in lesser
quantity as compared to the empty tubes. Within the connective tissue, the ﬁbroblast cells
were lying in an unorderly fashion and throughout many newly formed blood vessels, often
with a large lumen, were seen. Centrally in the connective tissue layer, again brown stained
material, surrounded by large number of inﬂammatory cells (Figure 5.6E) was observed.
The other three samples, to some extent, showed a similar presence of fatty tissue, inﬂam-
matory cells and some brown stained material. In these samples, however, the largest part
of the explants was ﬁlled with the same honeycomb-like structure as described before. The
honeycomb-like structure was considerably larger than that found in the empty tubes (Fig-
ure 5.6F). At higher magniﬁcation deep red staining around and as well as in the individual
compartments of the honeycombs, was seen, suggesting mineralization. Bone forming cells,
however, could not be observed, implying that the mineralized material was not bone-like
tissue. There were also no signs of inﬂammation (Figure 5.6G).
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Figure 5.4: Macroscopic ﬁndings after sacriﬁcing an empty tube specimen showed (A) only
staining of the subcutaneous tissue, (B) the COLLOSS R©E containing specimen showed a
bony consistence upon palpation and (C) within the COLLOSS R©E/ β-TCP mixture, the
β-TCP granules were clearly visible in the subcutaneous tissue.
Figure 5.5: Microtomographic images of (A) an empty tube showing no radiopaque tissue,
in contrast to the (B) COLLOSS R©E-containing specimen and the (C) COLLOSS R©E and
β-TCP mixture.
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Figure 5.6: Light micrographs of (A) an empty collagen tube (magniﬁcation 1x) showing
fatty tissue (f) surrounded by a ﬁbrous tissue capsule (c) with centrally a speciﬁc tissue
zone. (B) Detail of A, showing brown stained material (b) which could be recognized as
remnants of the mineralized collagen or hematoma (magniﬁcation 20x). (C) Detail of A,
showing a honeycomb-like structure (h), consisting of a skeleton of mineralized collagen in
which the internal structure of each “cell” was ﬁlled with immature connective tissue. The
mineralized collagen did not contain osteoblasts and osteoclasts, neither bone marrow-like
tissue nor deposits of osteoid. (magniﬁcation 10x). (D) A COLLOSS R©E in collagen tube,
note the lesser fatty tissue that was present as compared to the empty tubes (magniﬁcation
1x). (E) Detail of D , showing the same presence of brown stained material as in the
empty tubes (magniﬁcation 20x). (F) A COLLOSS R©E specimen, showing a larger part of
the same honeycomb-like structure as described in C (magniﬁcation 1x). (G) Detail of F,
showing evidence of mineralization (m) – also within the cell -still without bone forming cells
(magniﬁcation 20x). (H) A COLLOSS R©E and β-TCP in collagen tube specimen, showing
the β-TCP granules (g) grouped together (magniﬁcation 1x). (I) Detail of H, showing no
signs of osteoconductivity at the border of the β-TCP granules (magniﬁcation 10x).
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5.3.3.3 COLLOSS R©E and β-TCP-ﬁlled collagen tubes
In the third group, all six samples showed a similar result. A very thin connective tissue
capsule of 4-6 layers in thickness surrounded the entire explants (Figure 5.6H). Within the
explants, the β-TCP phosphate granules were always grouped together. In between the
granules, an immature unorganized connective tissue was present with many newly formed
blood vessels and some inﬂammatory cells. The connective tissue followed the contour of
the individual granules closely, but no signs of osteoconductivity nor of osteoinductivity
was seen (Figure 5.6I). Separate from the granules, the same honeycomb-like structure was
seen, again suggesting the presence of mineralized tissue. No bone forming cells could be
observed.
5.3.4 Histomorphometric evaluation
Since no bone formation had occurred, the histomorphometric analysis planned initially, was
abandoned.
5.4 Discussion
In this study, degradable mineralized collagen tubes, β-TCP granules and COLLOSS R©E
were implanted in ectopic sites in rats. It was intended to study a possible increase of the
amount of bone formation as compared to previous studies10,18, showing the osteoinductive
capacity of COLLOSS R©E in a titanium carrier. Although the same ectopic rat implantation
model was used, the results of the current study were negative as no bone was formed in
any of the experimental groups. The 2nd and 3rd initial hypotheses, therefore, that more
bone formation was expected when the amount of COLLOSS R©E had increased and that
β-TCP would facilitate the ingrowth of bone cells, could not be conﬁrmed.
The diﬀerent results, as compared to earlier studies, could be explained by the mechanical
properties of the mineralized collagen vs. titanium ﬁbre mesh. Perhaps the collagen scaﬀold
allows for more migration of the COLLOSS R©E from the implant site, as compared to the
stable titanium, as was used before. The mechanical instability of the mineralized collagen
could also have prevented the ingrowth of bone. However, it is more likely that the diﬀerence
can be explained by its degradation characteristics.
In retrospect, the microCT study did not prove to be useful. It was planned, however, to
study possible bone ingrowth as was expected.
In the present study, the mineralized collagen tubes appeared to have disintegrated after
12 weeks. This went along with macroscopically visible inﬂammatory reaction in each of
the three groups. Since this was not seen in our previous experiments with the titanium
carrier10,18, it seems likely that the novel collagen carrier had acted as a foreign body. The
β-TCP is unlikely to have caused this reaction, since the reaction also occurred in the
animals without β-TCP implantation. The subsequent inﬂammatory reaction around the
collagen tube, was apparently enough to preclude possible bone induction by COLLOSS R©E.
The tubes made of mineralized collagen type I have been developed to act as a mechanically
stable but biodegradable support which should facilitate the application of COLLOSS R©E and
provide the possibility for proper ﬁlling of bone defects, allowing for complete replacement
of the synthetic graft material by vital bone tissue7. COLLOSS R©E alone has a cotton-wool
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like morphology and does not fulﬁll this purpose because it collapses immediately after
contact with ﬂuids. Mineralized collagen type I was chosen as support material because
it mimics the composition of extracellular bone matrix (nanocomposite of collagen and
hydroxyapatite) and it is also readily degradable and can be completely remodeled into
bone tissue4 5. In the present study, an equine source of collagen was chosen in order to
match the COLLOSS R©E material.
There is only one study that combined the mineralized collagen and COLLOSS R©E like in
the present study7. This study, however, only involved a cell culture with human bone
marrow derived stroma cells. The osteoinductive nature of COLLOSS R©E was conﬁrmed
by a signiﬁcant higher activity of the osteogenic marker alkaline phosphatase (ALP), while
inhibiting cell proliferation. This is in line with our previous studies as well9.
Still, there are several studies that make use of mineralized collagen to evaluate its possible
suitability as a bone substitute7,3. Using osteoblasts and osteoclasts it was shown that a
mineralized collagen scaﬀold could completely be remodeled into vital bone tissue, suggest-
ing that collagen could act as a suitable scaﬀold in bone tissue engineering. Another four
studies evaluated mineralized collagen in in vivo studies, in which 2 experimental groups
were tested in ectopic sites and 3 in orthotopic sites12,19,14,13. The results in ectopic sites
are similar to our current ﬁndings as they indeed report inﬂammatory reaction, resulting in
complete phagocytosis of the collagen without any signs of bone formation19,14. The results
in orthotopic sites, are inconsistent. Schliephake et al.13 reported no enhancement of bone
formation by mineralized collagen, when implanted in rat mandibles. After implantation
in rat calvarial defects12 it was found that an inﬂammatory reaction had inhibited early
stages of bone healing. This ﬁnding is comparable to the present data. Yet, after complete
resorption of the collagen in the calvarial defect model, an increase in bone formation was
described. Yokoyama et al.19 studied bovine collagen in rat femur defects and the results
are comparable with those of Schliephake et al.12 and showed resorption of the collagen
and replacement by new bone. In other words, the results of the mineralized collagen
nanocomposite as a scaﬀold are inconsistent as far as the occurrence of inﬂammation and
the enhancement of bone formation is concerned. In the present study, however, a novel
but lesser characterized equine collagen was used. It could be possible that impurities of
the the diﬀerent collagen preparation in the diﬀerent studies might have led to the observed
inﬂammatory reactions. In addition, the nanoscopical hydroxyapatite crystals (as part of
the mineralized collagen) might have caused an irritation when implanted in soft tissue.
It can still also be argued that instead of the collagen carrier, the increased amount of
COLLOSS R©E as used in the current study (40 mg versus 20 mg in the titanium carrier
in previous reports) could have inﬂuenced the results presented. It was, therefore, decided
to add an additional control experiment. In a separate group of rats, eight implants were
placed, i.e. four mineralized collagen and four titanium mesh tubes. They were ﬁlled with
either 20 or 40 mg of COLLOS R©E. In this control experiment, in three out of four of the
titanium tubes ﬁlled with COLLOSS R©E, newly formed bone like tissue was seen (Figure
5.7). In the collagen tubes no bone tissue was observed at all. Since all bone was only
detected inside of the titanium tubes, this additional experiment conﬁrmed not only the
data as obtained in our previous studies, in which titanium ﬁber mesh was used a scaﬀold
material, but underscored also that the carrier material can have a serious eﬀect on the
ﬁnal outcome of growth factor based bone engineering. Preferably, additional experiments
had to be performed to make direct comparisons between titanium and collagen in order
to determine the extent of inﬂammation and how this relates to the inhibition of bone
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Figure 5.7: Light micrograph of a titanium ﬁber mesh tube, ﬁlled with 40 mg COLLOSS R©E,
showing (A) the formation of new bone tissue. Black dots indicate the titanium mesh ma-
terial (t), red area showing the presence of newly formed bone-like tissue (n) (magniﬁcation
2.5x); (B) Detail of A, showing evident presence of osteocytes (o), embedded within a
mineralized matrix (m), as well as bone marrow-like tissue (bm) (40x).
formation. However, as no bone formation was found in any of the mineralized collagen
samples, such an experiment was not done. Such further investigations to the eﬀect of
separate parameters on the experimental outcome of animal studies are not allowed by the
local animal ethical committee, when the previous data indicated already unfavorable results.
Nevertheless, the limited additional study revealed that the biodegradable collagen carrier
and not the increased amount of COLLOSS R©E had inhibited the osteoinductive capacity
of COLLOSS R©E. It can thus be concluded, that the ﬁrst hypothesis, i.e. the expectation
that equine mineralized collagen tubes as used in this study, will act as a suitable carrier for
COLLOSS R©E, has to be rejected as well.
5.5 Conclusion
The osteoinductive capacity of COLLOSS R©E can be inhibited when the carrier chosen
gives rise to a signiﬁcant inﬂammatory reaction. Further studies are therefore necessary to
assess the eﬀect combining COLLOSS R©E with a dimensionally stable and osteoconductive
material, as well as the eﬀect of an increased amount of COLLOSS R©E.
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Healing of bone defects in the goat mandible, using COLLOSS R©E and
β-tricalciumphosphate
6.1 Introduction
Reconstruction of lost parts of the facial skeleton usually requires bone grafts taken from
donor sites. Donor site morbidity and limited availability are, however, complicating factors.
As a consequence, there is an ongoing search for bone substitutes to avoid the need for
bone harvests. Researchers have tried to produce biologically active, i.e. cell- and/or growth
factor loaded scaﬀolds to produce new bone tissue. Previous studies have shown that a
material derived from bovine sources (COLLOSS R©) behaved as an osteoinductive material
in an ectopic site in rats21. Because of the risk of Bovine Spongiform Encephalopathy
(BSE), a similar equine material, COLLOSS R©E, consisting of a lyophilized complex of an
extracellular matrix product extracted from diaphyseal equine bone, was studied in the same
model18. This equine material also showed osteoinductive properties. There is no Transient
Spongiform Encephalopathy (TSE) known in horses according to the reports of the Oﬃce
International des Epizooties10,22. TSE is only known to occur in bovines, sheep, goats,
cervids, farmed minks, domestic cats and exotic ungulates in zoos10,22. An in vitro analysis
of COLLOSS R©E revealed that COLLOSS R©E is a rich source of TGF-β1 but also contains
the growth factors TGF-β2, BMP-2, BMP-3, BMP-7, IGF-1 and possibly VEGF17.
The amount of ectopic bone found in the previously mentioned studies was, however, some-
what limited. The limited new bone formation can be explained by the lack of osteoconduc-
tive properties of the scaﬀold. A scaﬀold usually acts as a 3-dimensional frame, facilitating
ingrowth of bone forming cells, resulting in an increased amount of new bone. Calciumphos-
phate materials are known to possess such osteoconductive properties15,19,4. In particular,
β-Tricalcium-Phosphate (β-TCP) or biphasic materials are often used.
It has also to be emphasized that in the two rat studies mentioned above, there was ectopic
bone formation as a result of both bovine and equine COLLOSS R© application21,18. How-
ever, to investigate its possible clinical application, COLLOSS R©E also needs to be tested
in an appropriate bone defect in a large animal model. The goat was selected for this
experiment because adult goats have a similar body weight as humans and their bones
have dimensions suitable for the placement of rather large implants. They are also con-
sidered to have a metabolic and bone remodeling rate similar to that of humans. Goats
and the very similar sheep model are used in 12% of orthopaedic research16,14,1. The aim
of this experiment was to study bone formation in bony defects of a goat mandible with
COLLOSS R©E in combination with an osteoconductive scaﬀold (β-TCP). The hypothesis is
that COLLOSS R©E in combination with β-TCP will result in more new bone than without
the scaﬀold.
6.2 Material and methods
6.2.1 Implants
COLLOSS R©E (OSSACUR AG, Oberstenfeld, Germany) was extracted from the extracellular
matrix of equine long bones (i.e. humerus, radius, metacarpus, femur, tibia, ﬁbula, metatar-
sus) of foals younger than 12 months of age. Only the compact bone of the diaphysis was
processed. The lyophilizate was a collagenous matrix, consisting of type I collagen chains
with other insoluble proteins. All processing was performed under aseptic conditions. On
cadaver bone, a series of sample defects ﬁlled with diﬀerent amounts of the material, were
prepared. Based upon these studies, the manufacturer advised that 80 mg was an optimal
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amount to get a similar defect ﬁlling and material compression as is used for the treatment
of non-healing fractures (for which indication the standard material is CE approved). Hence,
a standardized amount of 80 mg was always used.
The ceramic that was used consisted of irregular granules of pure β-tricalciumphosphate,
with a diameter of 1.5 – 3 mm. The interconnected porosity was about 70%, with pores
1– 600 μm in diameter. The calcium phosphate is completely resorbable and has fully
interconnected porosity, which is thought to promote the osteoconductive properties of the
material (CAM Implants BV, Leiden, The Netherlands).
For one of the study groups, 80 mg of COLLOSS R©E was mixed with 2 mL of β-tricalcium-
phosphate granules by hand for a standardized time of 2 minutes. The volume of the
mixture was standardized with the help of a special instrument that corroborated with the
volume of the defect, i.e. 17 mm diameter and 10 mm in height (Figure 6.1).
BIO-GIDE R© (Geistlich Pharma AG, Switzerland) is a collagen membrane, extracted from
veterinary certiﬁed pigs and is puriﬁed to avoid antigenic reactions. The porous surface,
facing the bone, is meant to allow the ingrowth of vascular tissue. The dense surface,
facing the soft tissue, is meant to prevent ingrowth of ﬁbrous tissue in the bone defect.
The membrane is made of collagen types I and III without further crosslinking or chemical
treatment.
6.2.2 Animal model and implantation procedure
Sixteen healthy, skeletally mature, female Saane goats were used for the implantation study
in a split jaw design to exclude cross-over eﬀects. Approval was obtained from the Radboud
Figure 6.1: Instrument used for standardized applying of material into the defect (17 mm
diameter and 10 mm height).
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Figure 6.2: (A) Using a template and trephine drill, a standardized bony defect (17 mm in
diameter) was created in the angulus mandibulae, surrounded by four titanium pins. (B)
The COLLOSS R©E-β-TCP mixture has ﬁlled the defect. (C) The collagen membrane placed
at the lateral site, is ﬁxed by the four titanium pins. (D) The defect is closed in layers.
University Nijmegen animal ethics committee (RUDEC 2004-2) and the national guidelines
for the care and use of laboratory animals were obeyed. Surgery was performed under general
anesthesia. The area of the angle of the mandible was bilaterally shaved, washed and dis-
infected with povidone-iodine. Submandibular incisions were made and skin, subcutaneous
tissues and periosteum were reﬂected to expose the mandible.
Round through-and-through holes, with a diameter of 17 mm were drilled in the angle of
the mandible using a trephine burr. Four small diameter titanium pins (Stabilok R©, Fairfax
Dental, Inc.) were simultaneously placed around the defect in a standardized manner, using
a template, in order to be able to recover the defects after sacriﬁcing the animals (Figure
6.2A). The defects were subsequently ﬁlled (Figure 6.2B) in a randomized design, as shown
in Table 6.1.
Preceding the drilling, a BIO-GIDE R© membrane was placed to cover the bony defect at the
buccal side (Figure 6.2C) and to support the periosteum that was lifted. At the lingual site,
the periosteum was approached with great care and eﬀorts were made to avoid damaging
it when drilling the holes. This was conﬁrmed by clinical observation during the drilling
procedure. The wounds were closed in layers using a standard suturing technique (Figure
6.2D). All animals were sacriﬁced after nine weeks, and the area of the mandible where the
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defects were located was dissected. The overlying soft tissues were removed, taking care
not to disrupt the overlying periosteum.
6.2.3 Radiographs
Immediately after surgery, plain radiographs were taken to conﬁrm proper positioning of the
defect, especially in relation to the mandibular canal. Just before sacriﬁce after nine weeks,
radiographs were again taken from the samples to evaluate possible bone growth.
6.2.4 Micro-computed tomography
The tissues were ﬁxed in 4% buﬀered formalin for two days and then placed into 70% alcohol.
The specimens were then scanned using computed microtomography (μ-CT; Skyscan-1172,
Skyscan NV, Aartselaar, Belgium) in order to study possible regenerated bone architecture.
To analyze the amount of de novo bone formation, i.e. not arising from ingrowth from the
defect edge but new bone formed within the centre of the defect, a method was adapted
from von Doernberg et al., 20065. For these measurements a 4 mm diameter and 5 mm
high cylindrical area of interest was placed centrally in the original defect, after which the
percentage of radiopaque material was measured.
6.2.5 Histological and histomorphometric procedures
After μ-CT imaging, specimens were dehydrated in a series of ethanol and embedded in
methyl methacrylate (MMA). After polymerization, 10-15 μm sections of all defects were
cut in a plane perpendicular to the buccal plate using a modiﬁed diamond blade sawing
technique13. The sections were stained with methylene blue basic fuchsin6. At least three
sections were cut at the centre of the defect. All histological sections were digitally pho-
tographed and assessed by three reviewers. On 10x magniﬁcation the areas of newly formed
bone were also selected and the amount of bone was measured in mm2 within a chosen
region of interest (17 x 5 mm) (Scion Image, Scion Corp, Frederick, MD).
6.2.6 Statistical analysis
For the statistical analysis of the micro-computed tomography a Student’s t-test and for
histomorphometry an ANOVA with post-hoc Tukey test were used. In all cases data are
expressed as mean values ± SD and the level of signiﬁcance was set at p<0.05.
6.3 Results
6.3.1 Macroscopic ﬁndings
All 16 goats remained in good health during the nine weeks of evaluation. In all of
the animals considerable swelling occurred at the side of the jaw corresponding with the
COLLOSS R©E implanted sites (Figure 6.3). Despite this swelling, the animals ate normally.
After approximately two weeks, the swelling had disappeared in all animals. The explanted
parts of the mandible ﬁlled with COLLOSS R©E (with or without the β-TCP scaﬀold) showed
abundant periosteal bone formation as compared to the specimens without COLLOSS R©E.
84
Healing of bone defects in the goat mandible, using COLLOSS R©E and
β-tricalciumphosphate
6.3.2 Radiographic evaluation
All postoperative radiographs showed intact mandibular canals, conﬁrming that none of the
bony defects had exposed the inferior alveolar nerve. They also showed that the 17 mm
defect could be considered a non-healing defect for the nine weeks healing period as none
of the eight empty defects was completely ﬁlled with bone. The position of the titanium
markers was the same as immediately postoperatively. Apart from a small radiolucent area
in the centre, the empty defects were ﬁlled with a radiopaque material, while the edges
of the original defect remained visible. The defects ﬁlled with COLLOSS R©E showed a
similar radiolucent centre as compared to the non-ﬁlled defects. The β-TCP granules were
clearly visible in the other two groups. The original borders of the defect were again clearly
distinguishable.
6.3.3 Micro-computed tomography evaluation
The 3D images (Figure 6.4) showed several diﬀerences between the various study groups.
The non-ﬁlled control defects showed considerable lateral ingrowth of bone, although cen-
trally an empty space always remained. The defects ﬁlled with COLLOSS R©E alone showed
a similar lateral ingrowth with a central radiolucent area. The β-TCP alone showed a gran-
ular ﬁlling of the defects. The COLLOSS R©E/β -TCP mixture showed a blend between the
two latter groups; i.e. ingrowth from the edges, an amorphous ﬁlling of the defects with
radiopaque material (either new formed bone / granules), as well as radiolucent areas in
between. The quantiﬁed measurement in the central zone revealed that COLLOSS R©E had
given rise to a small amount of new bone formation within the defect, i.e. 4.61% vs. 0.56%
radiopaque material in the control defects (p=0.042).
6.3.4 Descriptive histological evaluation
When processing the histological slides of the 16 animals, it became clear that the embedding
procedure had not resulted in fully adequate MMA penetration and/or polymerization in
the center of the samples. This resulted in sometimes thicker sections in the centre of the
defects, which was a disadvantage when observing, especially at higher magniﬁcation. In
general, within the eight samples of each group, a similar tissue reaction was seen, whereas
diﬀerences amongst the four groups were evident:
• In the non-ﬁlled control group, the edges of the original defect were clearly distinguish-
able, due to the speciﬁc structure and lighter staining of the bone matrix. From the
edges of the original defect, newly formed bone had always grown towards the center.
This bone was characterized by a bright blue staining of the nuclei and generally less
dense and thus darker stained in comparison to the original bone. The ingrowth as
seen in the histology was in keeping with the observations made on the radiographic
and μ-CT images. All histological slides showed a central space of ﬁbrous connective
tissue. No complete ﬁlling of the defects with bone was observed in any of the sam-
ples. The connective tissue present showed no or only mild inﬂammatory reaction,
although speciﬁc evaluation was somewhat hampered by the thickness of the slides
(Figure 6.5A).
• In the group ﬁlled with COLLOSS R©E bone ingrowth was also seen (Figure 6.5B).
However, the central area ﬁlled with connective tissue seemed similar to the non-ﬁlled
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Figure 6.3: Clinical ﬁndings of goat no. 5, two days postoperatively. Note the considerably
swelling at COLLOSS R©E-treated right side, which occurred in the ﬁrst week. No swelling
was seen at the left side containing a β-tricalcium phosphate ﬁlled defect.
Figure 6.4: (A) Microtomopgraphic image of an empty defect (0,56% of radiopaque material
in the centre). (B) COLLOSS R©E ﬁlled defect (4.61% of radiopaque material in the centre;
signiﬁcant diﬀerence from empty p=0.042). (C) β-TCP ﬁlled defect. (D) COLLOSS R©E
and β-TCP mixture ﬁlled defect. The red line in A indicates the sectioning plane as used
for the histological preparation.
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Figure 6.5: (A) Light micrograph of histology of an empty defect (magniﬁcation 1,6x). (B)
COLLOSS R©E ﬁlled defect, arrow indicates bone marrow-like tissue (magniﬁcation 1,6x).
(C) β-TCP ﬁlled defect (magniﬁcation 1,6x). (D) COLLOSS R©E and β-TCP mixture ﬁlled
defect (magniﬁcation 1,6x).
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controls. Loose ﬁbers or patches of brown-stained COLLOSS R©E material were still
present. Aside from the bony ingrowth from the border, in 6 of the 8 samples in this
group islands of newly formed bone were also seen which were not connected to the
lateral defect edges. This tissue was characterized by the presence of osteocytes in a
mineralized matrix, as well as clear areas with bone marrow-like structure.
• In the β-TCP ﬁlled group, again the edges of the originally created defect were clearly
observable. There was considerable bone ingrowth originating from the defect edges.
Inside the defect area, the granular β-TCP material was clearly present. Sometimes,
the granules were divided in smaller clusters surrounded by connective tissue. The
area in between the granules was always ﬁlled with connective tissue. This connective
tissue had an immature aspect with loose organization. No clear inﬂammatory reaction
around the β-TCP granules was seen (Figure 6.5C).
• In the COLLOSS R©E/ β-TCP mixture -ﬁlled defects a more inconsistent tissue reaction
was observed. From the edges of the original defect, newly formed bone had grown
towards the center. Inside the defect granular material was also present, however, less
as compared to the β-TCP group. Patches of brown-stained COLLOSS R©E material
were occasionally present. In this group separate areas of newly formed bone were
also seen that were not in connection with the edges of the defect (Figure 6.5D).
6.3.5 Histomorphometric evaluation
Figure 6.6 shows the histomorphometric results. In the chosen region of interest the per-
centage of bone surface was calculated. The non-ﬁlled control defects contained the highest
percentage of new bone (62%). The use of COLLOSS R©E alone resulted in 55% bone vol-
ume, which was not signiﬁcantly diﬀerent from the non-ﬁlled control group (p=0.34). The
β-TCP scaﬀold alone and the mixture of COLLOSS R©E/ β-TCP were similar and had a sig-
niﬁcantly lower volume of new bone of 38% (p=0.0029) and 36% (p=0.0057) respectively.
Table 6.1: a: defect ﬁlled with 80 mg COLLOSS R©E. b: defect ﬁlled with 80 mg
COLLOSS R©E + β-tricalcium phosphate. c: defect ﬁlled with β-tricalcium phosphate.
d: defect empty (control).
Goat no. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Left side a b b c c d d a a b b c c d d a
Right side c d d a a b b c c d d a a b b c
6.4 Discussion
The aim of this study was to evaluate the healing of bony defects in a goat mandible
with COLLOSS R©E alone and in combination with an osteoconductive scaﬀold (β-TCP)
in order to evaluate their healing capacity and combined action in relatively large osseous
defects. A diameter of 17 mm was the largest possible span in the angulus mandibulae
region without damaging the mandibular canal, which contains the inferior alveolar nerve.
This was conﬁrmed by previous research (data not shown). The defects of 17 mm appeared
to be non-healing for a period of nine weeks. The β-TCP granules were added to stimulate
bone formation because of their osteoconductive properties. This material is often used
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in clinical practice. Apart from the fact that the granules can help to maintain shape,
they can also retain the proteins in COLLOSS R©E for a certain period of time. Further,
there was chosen for a split jaw design in order to exclude cross-over eﬀects of the applied
COLLOSS R©E. Although, even in this design, systemic eﬀects of the released growth factors
can never be completely excluded. However, the independent vascularity of the left and
right side of the mandible as well as clearance of the released growth factors via the internal
organs, makes such a scenario not realistic.
The results of this study revealed that COLLOSS R©E had a limited eﬀect on the growth
of new bone in the defects made but gave rise to considerable periosteal bone formation.
The non-ﬁlled control defects showed bone ingrowth from the edges, resulting in the largest
volume of new bone (62%). The addition of β-TCP did not result in the expected synergy,
in that the healing of the defect had not improved but seemed even to be inhibited (38%
of new formed bone). The defects ﬁlled with COLLOSS R©E, with (36% of new formed
bone) or without (55% of new formed bone) the osteoconductive material, had islands
of newly formed bone not connected with the defect edges. The hypothesis, therefore,
that COLLOSS R©E with the addition of an osteoconductive material, i.e. β-TCP, would
result in more new bone than without can therefore not be accepted. There certainly
was a positive eﬀect of COLLOSS R©E, however, in that islands of new bone were seen
inside the centre of the defects treated with COLLOSS R©E. As shown by the micro-CT
assessment, the COLLOSS R©E-ﬁlled defects contained signiﬁcantly more bone in the centre
of the defect as compared to the empty defects (4,61% vs 0,56%). In the empty defects, the
newly formed bone appeared to grow from out of the edges of the defect. Unfortunately,
similar microtomographic quantiﬁcation was not suitable for both groups containing β-
TCP, because the bone mineral and the β-TCP granules were of equal radiopacity, whilst
the stacking of the β-TCP granules already gave substantial spreading of the measurements.
Hence, no quantitative analysis was possible in these groups.
There might be several reasons for these unexpected results. First, the used amount of
COLLOSS R©E may not have been appropriate for this experimental animal model, yet the
amount used was four times more than the amount used in a rather successful rat exper-
iment17. This was based on the volume of the created orthotopic defect. Second, the
amount of COLLOSS R©E used may have caused an adverse eﬀect in the early stage of
healing with regard to the considerable soft tissue swelling as compared to the sites where
no COLLOSS R©E was used. It can be assumed that the swelling was due to an initial
foreign body reaction that subsided over time. It is also possible that the used amount of
COLLOSS R©E, containing growth factors, accelerated the metabolic rate of many other cells
as well, resulting in considerable tissue swelling. A titration study using diﬀerent amounts
of COLLOSS R©E should address this question. Third, the mixing of the granules with the
COLLOSS R©E, appeared to be diﬃcult. The two materials did not mix very easily, which
may have caused uneven distribution in the defects and may also have inﬂuenced the results.
Further studies are necessary to facilitate and optimize the production and processing con-
ditions of β-TCP - COLLOSS R©E mixture. Concentrations of growth factors in the mixture
should also be assessed and optimized. To facilitate this, β-TCP granules could be coated
or impregnated with COLLOSS R©E by co-lyophilization to improve its application. Finally
there might have been some eﬀect of the BIO-GIDE R© membrane, which was placed in
order to keep the bone substitute in place and prevent soft tissue ingrowth. The membrane
separates the periosteum from the defect and also inhibits, to some extent, stem cell migra-
tion into the area as induced by the BMPs. In our previous study, titanium was used as a
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Figure 6.6: The calculated percentage of new bone in histological slides. Data are expressed
as mean values ± SD. Non-ﬁlled versus COLLOSS R©E alone is not signiﬁcant (p=0.34). Non
ﬁlled versus β-TCP (p=0.0029) or versus the mixture of COLLOSS R©E/ β-TCP (p=0.0057)
are both signiﬁcantly diﬀerent.
carrier for COLLOSS R©E. For clinical applications, however, a degradable scaﬀold material
sometimes is preferred. For this reason, it was chosen in this study to use degradable ma-
terials only. The used collagen membrane, as well as the lingual periosteum, were thought
to maintain the COLLOSS R©E and β-TCP granules in place. In contrast to titanium, the
collagen membrane did not enable cellular migration, as compared to titanium and this can
be seen as a drawback.
Bone substitutes like β-TCP granules provide initial stability and are supposed to be osteo-
conductive. The present results, however, showed almost no sign of osteoconduction and
it even appeared that the granules hampered the ingrowth of bone in the defects. Never-
theless, β-TCP is known to act as an osteoconductive material rather than a bone growth
inhibitor3,2. The obvious inhibiting eﬀect as seen in this study is therefore unexpected. A
possible explanation is that shortly after surgery there is no tissue ingrowth in the defect
yet. The highly mobile lingual tissues could therefore have bulged into the bone defect. The
combination of these soft tissues and movement of the β-TCP granules during chewing may
have caused an inﬂammatory response, resulting in delay of bone ingrowth. The placement
of a collagen membrane on the lingual side could have prevented this. Histological data,
however, of specimens with a short implantation period are lacking to prove this hypo-
thesis. Still, support for this explanation is provided by the observation that the addition
of COLLOSS R©E to the β-TCP granules seems to partially undo this inhibitory eﬀect. The
addition of COLLOSS R©E apparently limited the mobility of the granules.
The abundant periosteal bone formation, as seen in the goats treated with COLLOSS R©E,
is somewhat puzzling when considering the relative lack of bone formation in the defects
itself. This might, however, be the result of the relatively large amount of TGF-β1 as found
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in COLLOSS R©E17. Release of the TGF-β1 can result in callus formation as TGF-β1 is
known to modulate the early stages of bone formation by recruiting osteoblast progenitors
and stimulating their proliferation.
Unfortunately, it was not possible to quantify the periosteal bone formation since it was
necessary to expose the titanium pins that were inserted as a reference for the radiographs
and to hold the BIO-GIDE R© membrane in place. It was necessary to remove the titanium
pins before starting the μ-CT recording to avoid scattering artifacts. The used pins are
regularly used for the ﬁxation of plastic dental restorations. Unfortunately, such pins cannot
be unscrewed after installation. This implied that parts of the newly formed periosteal bone
had to be removed.
There are several studies proving the osteoinductive capacity of COLLOSS R©E in ectopic
sites21,18,11,20,7. The three studies found on orthotopic sites8,9,12 reveal ambiguous results.
The results of Kawcak et al.9 are in agreement with the results of the present study. They
compared the use of COLLOSS R©E to autogenous bone, but they used a rib-defect model in
horses. They could not prove any enhanced healing associated with the use of COLLOSS R©E.
The defects treated with autogenous bone and empty controls showed a greater percentage
of bone as compared to the defects treated with COLLOSS R©E. Proper comparison of the
used amount of COLLOSS R©E compared with our study is not possible as the material
was delivered in a diﬀerent shape. In contrast, the studies done by Huﬀer et al.8 and Li
et al.12 show improved bone healing when using COLLOSS R©E. Huﬀer et al.8 used sheep
long bone cortical defects to compare COLLOSS R©E, bovine COLLOSS R©, sintered β-TCP
and fresh iliac autografts. They concluded that COLLOSS R©E and bovine COLLOSS R© had
similar eﬀects comparable with autografts but superior to β-TCP. The used concentration of
COLLOSS R©E was about 5x as high as the concentration used in our study. Li et al.12 used
a spinal fusion model in pigs to compare COLLOSS R©E to autograft. After three months,
both materials achieved the same fusion rate. However, the concentration of COLLOSS R©E
was similar to our study, Therefore, we suppose that several diﬀerences in study design,
such as animal model, defect size and surgical site could have contributed to the diﬀerences
found in results between these three studies and the present study.
6.5 Conclusion
The results of the present study are somewhat unexpected in that empty bone defects in
the goat mandible showed the most bone ingrowth, which was always connected to the
defect edges. This is in contrast to the eﬀect of COLLOSS R©E, with or without β-TCP,
which induced bone formation in the center of the defects. Further studies about the use of
diﬀerent amounts of COLLOSS R©E as well as production and processing conditions of the
β-TCP/COLLOSS R©E mixture, including the use of other animal models and implantation
sites, are necessary to examine the suitability of COLLOSS R©E for bone regeneration.
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7.1 Summary and address to the aims
In reconstructive surgery of the maxillofacial skeleton, the use of autogenous bone is still
to be considered the gold standard. Harvesting bone, however, goes along with donor site
morbidity and requires extra operation time. For this reason, it still remains a challenge
to bridge bony defects without the use of autogenous grafts. This has lead to an ongoing
search for the ideal bone substitute. The ideal bone substitute should mimic the osteogenic
capacity of autogenous bone. Several materials such as polymers, calciumphosphates and
bioactive glass, have already been assessed whether they could serve this purpose. The
bone substitutes currently available, are only osteoconductive at best and it is unlikely that
more promising osteoinductive bone substitutes will become available in the near future.
An alternative approach includes bone engineering. With regard to this technique, three
components are necessary, i.e. growth factors, vital bone-forming cells and a scaﬀold to al-
low for the formation of new bone in a desired location and shape. Growth factors are bone
inducing substances, which can make mesenchymal cells to diﬀerentiate into osteoprogeni-
tor cells and can be used for the chemical stimulation of bone formation. At present, several
growth factors have already been identiﬁed and made available by recombinant technology,
of which the bone morphogenetic proteins (BMPs) have the most potential. The disadvan-
tage of recombinant growth factors, as compared to naturally derived ones, is the fact that
they are rather expensive. Single growth factors are also less eﬀective, as compared to the
mixture of growth factors in naturally derived sources.
Bone substitutes may be loaded with growth factors, which would make them osteoinduc-
tive. This, may in time, circumvent the need for harvesting of autogenous bone. Several
experiments have already been done to assess the eﬀectiveness of combinations of bone sub-
stitutes and several growth factors. As yet, the ideal combination has not been detected.
In this thesis, COLLOSS R©E material was chosen to serve as a source for naturally derived
growth factors and the main objective was to evaluate the potential of this material for
reconstructive purposes.
In Chapter 1, a description of COLLOSS R©E is presented, as well as the rationale for the
research, whereas the basic principles of bone healing and bone tissue engineering are also
described. Scientiﬁc evidence to support the eﬀectiveness of COLLOSS R©E in bone tissue
engineering, should be provided by in vitro as well as in vivo animal experiments, before
studies on human beings may be contemplated. In the search for this evidence, the following
research questions were addressed:
Aims: 1. What bone substitutes and growth factors are currently available for the purpose
of bone tissue engineering?
In Chapter 2 an overview is presented of bone substitutes and growth factors presently
available for clinical application. The advantages and disadvantages of the various bone
substitutes such as allogenic and xenogenic bone and synthetic bone substitutes are dis-
cussed. It was concluded that bone substitutes based on calciumphosphates such as re-
sorbable tricalciumphosphate and non resorbable hydroxylapatite are currently best suited
for clinical use because they are the major component of bone tissue.
A brief history of the development of research on growth factors is presented. In particular
the working mechanism and the eﬀects in the cascade of bone formation of bone morpho-
genetic proteins (BMPs), transforming growth factor-β (TGF-β), ﬁbroblast growth factor
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(FGF) and platelet derived growth factors (PDGFs) are discussed. Most of these growth
factors are produced by recombinant techniques which makes them expensive, whereas in
clinical applications large quantities are needed. For this reason, naturally derived growth
factors, such as COLLOSS R©E, might be an alternative. In addition, the principles of bone
engineering is explained. With this technique, it is aimed to produce tissue at a desired
location that is functional and, thus, could probably replace the traditional autogenous bone
grafts.
2. Which diﬀerent growth factors are present in COLLOSS R©E and what is their action in
an in vitro cell culture experiment?
COLLOSS R©E, a lyophilized complex of the extracellular matrix proteins extracted from dia-
physeal equine bone, does contain native growth factors. In a series of experiments, as well
in vitro as in vivo, the utility of COLLOSS R©E as a growth factor source, should be further
evaluated. For this reason, growth factors in COLLOSS R©E were analyzed in Chapter 3, us-
ing ELISA tests, mass spectrometry / Western blotting and a 24-day cell culture experiment
using osteoblast-like cells. The results of the ELISA testing, mass spectrometry and western
blotting all conﬁrmed that TGF-β1 was the main growth factor in COLLOSS R©E at 55 ng
/ mg. The results from the culture test showed that the cell proliferation, alkaline phos-
phatase activity, and matrix calciﬁcation, as indicative factors for bone-like tissue formation,
were all drastically changed by the addition of COLLOSS R©E. These changes are similar to
the eﬀects of the addition of TGF-β1. It was, therefore, concluded that COLLOSS R©E is
a rich source of TGF-β1, but also contains the growth factors TGF-β2, BMP-2, BMP-3,
BMP-7, IGF-1 and possibly VEGF. Other growth factors might be present in COLLOSS R©E
as well, but were not identiﬁed due to inherent detection limits of the used ELISA and mass
spectrometry techniques. The number of osteoinductive factors in COLLOSS R©E causes a
synergistic eﬀect, explaining the new bone formation found in previously described in vivo
studies, with much lower growth factor concentrations as compared to recombinant BMPs,
used in similar studies.
3. Will COLLOSS R©E act as an osteoinductive material when implanted in an ectopic site,
using a small animal model?
In chapter 4, COLLOSS R©E was investigated in a small animal experiment. Disc- and tube-
shaped implants were made from titanium ﬁbre mesh. The central space of tubes was ﬁlled
and the discs were impregnated with the COLLOSS R©E material to assess osteo-induction.
These implants and non-loaded controls were implanted subcutaneously into the back of
Wistar rats. After implantation periods of two, eight, and twelve weeks, the implants were
retrieved and sections were made. Histology showed a thin ﬁbrous capsule surrounding the
titanium mesh and a very mild tissue reaction. The disc implants, loaded or non-loaded,
showed no bone formation at all. After two weeks of implantation 3 out of 5 of the loaded
tubes showed bone formation with a mean of 0,3 mm2 areas of new formed bone, after eight
weeks 3 out of 6 and 0,7 mm2, and after 12 weeks this increased to 6 out of 6 and 1,0 mm2.
In the non-loaded tubes only connective tissue in growth was seen. In conclusion, it was
demonstrated that COLLOSS R©E, loaded in a titanium ﬁbre mesh tube shows osteoinductive
properties.
4. What is the eﬀect of the use of a biodegradable carrier on the osteoinductivity of
COLLOSS R©E?
In chapter 5, the suitability of mineralized collagen, as a carrier for the native bone mor-
phogenetic protein (BMP) containing COLLOSS R©E, was evaluated in a rat subcutaneous
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implantation model, similar as described in chapter 4. Tubular shaped scaﬀolds were made
from mineralized collagen and either left empty (controls), ﬁlled with 40 mg COLLOSS R©E,
or ﬁlled with a mixture of COLLOSS R©E and osteoconductive beta-tricalcium phosphate (β-
TCP) granules. Six of all samples were implanted in 18 animals. During the implantation
period, macroscopic examination suggested inﬂammatory reaction. Histological evaluation
after 12 weeks conﬁrmed the presence of inﬂammatory cells. Although the mineralized scaf-
fold and β-TCP granules could clearly be seen, no new bone formation was found. This is
in contrast to the results described in chapter 4, using a similar set-up with a titanium mesh
as a scaﬀold in combination with COLLOSS R©E. It is concluded, therefore, that the osteoin-
ductive capacity of BMPs or more speciﬁcally COLLOSS R©E is inhibited when the carrier
gives rise to a signiﬁcant inﬂammatory reaction. Additional studies are necessary to as-
sess the eﬀect of combining COLLOSS R©E with a dimensionally stable and osteoconductive
material like β-TCP.
5. Is it possible to use COLLOSS R©E to promote bone formation in orthotopic defects in
large animals?
The study in chapter 6 was set up to examine the properties of COLLOSS R©E in an
orthotoptic site in conjunction with a β-tricalciumphosphate (β-TCP) scaﬀolding material.
Thirty-two 17 mm circular defects in goat mandibles were ﬁlled with COLLOSS R©E, β-TCP,
COLLOSS R©E + β-TCP, or left empty. After 9 weeks the results were quantiﬁed by micro-
computed tomography and histology. The empty defects contained the highest percentage
of new bone (62%). The β-TCP scaﬀold resulted in 38% (p=0.0029), the mixture of
β-TCP /COLLOSS R©E resulted in 36% (p=0.0057), while the use of COLLOSS R©E alone
resulted in 55% (not signiﬁcant p=0.34). These results show that addition of β-TCP did
not result in the expected synergy with regard to the healing of the defect and seemed even
to inhibit the healing process. On the other hand, the addition of COLLOSS R©E induced the
formation of small islands of new bone, not connected to the defect edges. This was not
observed in the specimens not containing COLLOSS R©E (4,61% of bone formation centrally
in the defect vs. 0,56%; p=0.042). In conclusion, the results of the present study are
somewhat unexpected in that the empty defects showed the most bone ingrowth; however,
this ingrowth was always connected to the defect edges. In contrast, the application of
COLLOSS R©E with or without β-TCP induced bone formation in the center of the defects
also, conﬁrming its osteoinductive capacity.
7.2 Conclusions
Because of the drawbacks inherent to the use of autogenous bone, as well as the use of bone
substitutes alone, engineering of bone to reconstruct lost parts of the skeleton, seems to be
a promising strategy for the future. The research conducted in this thesis provides evidence
that COLLOSS R©E could be used for this purpose. This evidence was demonstrated in in vivo
studies, in that COLLOSS R©E can act as an osteoinductive material. The osteoinductive
capacity of COLLOSS R©E can be attributed to the multitude of growth factors (TGF-β1,-2,
BMP-2, BMP-3, BMP-7, IGF-1 and possibly VEGF) and their possible interaction. Yet,
the main component of COLLOSS R©E is TGF-β1, as conﬁrmed by ELISA testing, mass
spectrometry and Western blotting. A cell culture test showed that the cell proliferation,
alkaline phosphatase activity and matrix calciﬁcation were all drastically changed by the
addition of COLLOSS R©E, mirroring the eﬀects of addition of TGF-β1. Other growth factors
might be present in COLLOSS R©E as well, but were not identiﬁed by the used techniques.
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The clinical evidence for the osteoinductive capacity of COLLOSS R©E was established by
implanting COLLOSS R©E in an ectopic site, which resulted in the formation of bone tissue.
In this in vivo experiment a non-degradable titanium carrier was used. For clinical applica-
tion, however, it may be better to use a degradable carrier. In another in vivo experiment,
therefore, COLLOSS R©E and a degradable collagen carrier were tested. The osteoinductive
capacity of COLLOSS R©E, however, appeared to be inhibited in this setting. An elevated
inﬂammatory response in the healing process was thought to have caused this inhibition.
Another hypothesis in this experiment was that adding an osteoconductive scaﬀold, ex-
isting of β-TCP granules, was thought to enhance the formation of bone by oﬀering a
3-dimensional structure for the ingrowth of bone. Unfortunately, the results did not conﬁrm
this hypothesis. The third hypothesis, that an increased amount of COLLOSS R©E would
result in a greater amount of newly formed bone, could also not be conﬁrmed in this study.
After the osteoinductive capacity of COLLOSS R©E was conﬁrmed in an ectopic site, an in
vivo experiment was set up, using an orthotopic site. The results of this study revealed some
new bone formation in the centre of the defect indicating the osteoinductive capacity of
COLLOSS R©E. The combination with β-TCP as an osteoconductive scaﬀold, did again result
in inhibition of the osteoinductive capacity of COLLOSS R©E. It can, therefore, be concluded
that COLLOSS R©E has enough potential to act as a stimulus for osteogenesis, but that the
chosen degradable carrier and osteoconductive scaﬀold did not meet the expectations.
7.3 Future perspectives
The major component of COLLOSS R©E appears to be TGF-β1. It is known that TGF-β1 is
mainly responsible for a mitogenic eﬀect on osteoblasts. The interaction of the various other
growth factors present in COLLOSS R©E with TGF-β1 is not fully understood. Their action
might be more important than thus far appreciated. Further research might clarify the
interaction between diﬀerent growth factors and their synergistic eﬀects. Future research,
using more advanced techniques than ELISA, mass spectrometry and Western blotting,
should also be done to identify possible other growth factors, present in COLLOSS R©E.
The in vivo experiments, as well in small as in large animals, all revealed the osteoinductive
capacity of COLLOSS R©E. The eﬀect of the used amount of COLLOSS R©E on the formation
of bone, however, is still unknown. A study to reveal the eﬀect of various amounts of
COLLOSS R©E was not included in this thesis. It is probably of great value to investigate
whether the eﬀect of bone formation is depending on the used amount of COLLOSS R©E
and future studies should be performed to test this hypothesis.
When COLLOSS R©E was implanted in a resorbable collagen carrier, the osteoinductive ca-
pacity was inhibited by an inﬂammatory reaction. Whether this should be contributed to
the used collagen carrier, the used amount of COLLOSS R©E or the osteoconductive scaﬀold
that was added, is not completely clear. A major drawback in the chosen study design was
the fact that more than one variable was introduced at the same time. Further research is,
therefore, needed to establish the true cause of this inhibition by testing only one parameter
at the time.
The results revealed that the chosen resorbable carrier did not meet the expectations. A
suitable carrier should prevent the rapid release of COLLOSS R©E from the area, to provide
proper stimulation and diﬀerentiation of osteoprogenitor cells. Subsequently, the degrada-
tion of the carrier should proceed at the same rate as the bone regeneration occurs. Future
100
Summary, address to the aims, conclusions and future perspectives
research should, therefore, focus on the development of such a carrier to enhance the clinical
use of COLLOSS R©E.
It was hypothesized that an osteoconductive scaﬀold could facilitate the formation of bone
by osteoinductive COLLOSS R©E. The results of this thesis, however, could not conﬁrm any
beneﬁt of the addition of osteoconductive calcium phosphate. It is possible that the ratio of
the mixture of β-TCP and COLLOSS R©E used, plays a role in the results achieved. Further
studies are necessary to assess the eﬀect of combining COLLOSS R©E with a dimensionally
stable and osteoconductive material. It was also found that the two materials did not mix
well. There is, therefore, a need to search for better production and processing conditions
of this mixture. Coating of β-TCP granules with COLLOSS R©E might be a solution for this
problem.
The study carried out on goats, in an orthotopic site, to test the eﬃcacy of COLLOSS R©E,
with and without β-TCP, revealed the osteoinductive capacity of COLLOSS R©E. In this
study, however, the formation of abundant periosteal bone due to COLLOSS R©E could not
be assessed, because the titanium markers had to be removed, which precluded proper
measurement. In future experiments, it would be of interest to quantify this periosteal
bone formation by using a diﬀerent technique. This by-eﬀect of COLLOSS R©E might be of
clinical signiﬁcance when dealing with bone defects, in which the periosteum is still intact.
In summary, there certainly is room for further studies on the eﬃcacy of COLLOSS R©E
because the material is naturally derived and thus, does not give rise to the much feared
TSE infection as is the case with bovine products. It is also much cheaper than recombinant
products, whilst COLLOSS R©E exists of a mixture of growth factors. This has the inherent
advantage of the positive eﬀects of the interaction of these growth factors, as compared to
the use of a single growth factor, by imitating the natural synergistic action as occurs in
bone healing. Further research should, however, focus on a step-by-step approach testing
the various variables. This may eventually lead to an usable product for a clinical setting.
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Samenvatting, evaluatie van de doelstellingen, conclusies en toekomstperspectief
8.1 Samenvatting en evaluatie van de doelstellingen
Voor reconstructies van het aangezichtsskelet, worden autologe bottransplantaten tot op
heden nog steeds als ‘de gouden standaard’ gezien. Het oogsten van autoloog bot gaat
echter gepaard met nadelen zoals de morbiditeit van de donorplaats en een verlenging van de
operatietijd met alle kosten van dien. Daarom wordt er nog steeds gezocht naar alternatieven
voor het gebruik van autoloog bot. Het ideale alternatief zou een botvervangend materiaal
zijn met exact dezelfde eigenschappen als botweefsel zelf. Verschillende materialen, zoals
polymeren, calciumfosfaten en bioglas zijn reeds onderzocht op hun capaciteiten om als
mogelijke botvervangers te dienen. Deze materialen zijn echter hoogstens osteoconductief
gebleken, maar bezitten geen botvormende eigenschappen.
Een alternatief voor het gebruik van botvervangers is de techniek van ‘tissue engineering’.
Deze techniek beoogt, met behulp van groeifactoren en levende botcellen op een matrix,
nieuw bot te laten vormen in de gewenste vorm en op de gewenste locatie. Groeifactoren
kunnen ongediﬀerentieerde stamcellen aanzetten om tot botvormende cellen te diﬀerentie¨ren
en stimuleren daarnaast de vorming van botweefsel. Op dit moment zijn er al vele groeifac-
toren ge¨ıdentiﬁceerd en ook nagemaakt door middel van recombinante gen technologie. Het
is gebleken dat van deze groeifactoren, de bone morphogenetic proteins (BMPs), het meest
eﬀectief zijn. Deze recombinante groeifactoren hebben als nadeel dat ze slechts eﬀectief
zijn in tamelijk hoge concentraties hetgeen ze kostbaar maakt. Natuurlijke bronnen van
groeifactoren bevatten vaak een mengsel van groeifactoren waardoor ze eﬀectiever zijn dan
e´e´n enkele recombinante groeifactor.
Botvervangende materialen kunnen worden ge¨ımpregneerd met groeifactoren om te proberen
ze zo osteoinductief te maken. Deze techniek zou in de toekomst de noodzaak tot het
oogsten van donor bot overbodig kunnen maken. In het verleden zijn er al enkele studies
gedaan om deze combinaties te testen, maar de ideale samenstelling is tot op heden nog
niet gevonden.
In dit proefschrift werd COLLOSS R©E, een natuurlijke bron van groeifactoren, gee¨valueerd
voor de mogelijke toepassing in de reconstructieve chirurgie.
In Hoofdstuk 1 wordt het materiaal COLLOSS R©E beschreven, alsmede de aanleiding
voor het doen van dit onderzoek. Verder worden de basis principes van de botgenezing
en de techniek van tissue engineering uitgelegd. Vo´o´r de eventuele klinische toepassing
van COLLOSS R©E zou er eerst wetenschappelijk bewijs moeten worden gevonden voor de
geschiktheid van het materiaal. Dit bewijs zou kunnen worden opgebouwd door eerst in
vitro experimenten uit te voeren en vervolgens in vivo studies, eerst in kleine en later in
grote proefdiermodellen. Omwille van deze opbouw, werden de volgende onderzoeksvragen
gesteld:
1: Welke botvervangende materialen en groeifactoren zijn er momenteel beschikbaar voor
de tissue engineering van bot?
Hoofdstuk 2 geeft een overzicht van de botvervangende materialen en groeifactoren welke
zijn beschreven in de literatuur. De voor- en nadelen van verschillende botvervangers, zoals
allogeen en xenogeen bot en synthetische materialen, worden beschreven. Uit deze literatuur
kan worden geconcludeerd dat botvervangers die zijn gebaseerd op calciumfosfaten, zoals
het resorbeerbare tricalciumfosfaat en niet-resorbeerbare hydroxylapatiet, het meest geschikt
zijn vanwege het feit dat ze qua structuur het dichtst bij botweefsel in de buurt komen.
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Er wordt ook een korte inleiding over de ontwikkeling van onderzoek naar groeifactoren
beschreven. Vooral de werkingsmechanismen van bone morphogenetic proteins (BMPs),
transforming growth factor β (TGF-β), ﬁbroblast growth factor (FGF) en platelet derived
growth factors (PDGFs) worden besproken. Vanwege de hoge kosten van recombinant ver-
vaardigde groeifactoren, lijken natuurlijke bronnen van groeifactoren, zoals COLLOSS R©E,
een goed alternatief. Ten slotte worden de basis principes van de techniek van tissue engi-
neering toegelicht. Het gebruik deze techniek zou op den duur het oogsten van donorbot
overbodig kunnen maken.
2: Welke groeifactoren bevat COLLOSS R©E en hoe is hun werking in een in vitro experi-
ment?
COLLOSS R©E is een gevriesdroogd product en wordt geproduceerd door extracellulaire
prote¨ınes vrij te maken uit pijpbeenderen van paarden, waarin de groeifactoren zich bevinden.
De klinische toepasbaarheid van COLLOSS R©E, als bron van groeifactoren, zou in in vitro
en in vivo experimenten moeten worden onderzocht. De precieze inhoud van COLLOSS R©E
werd daarom in hoofdstuk 3 eerst geanalyseerd door middel van ELISA, massaspectometrie
en western blotting en in een 24-uurs celkweek met osteoblasten. Al deze experimenten
bevestigden dat met 55 ng/mg, TGF-β1 de belangrijkste groeifactor in COLLOSS R©E vormt.
Uit de celkweek kon worden geconcludeerd dat toevoeging van COLLOSS R©E ertoe leidde
dat de cel proliferatie, alkaline fosfatase activiteit en matrix calciﬁcatie, als indicatoren voor
het proces van botvorming, duidelijk veranderde. Deze veranderingen waren gelijk aan die
van de toevoeging van TGF-β1. Uit deze experimenten kan worden geconcludeerd dat
COLLOSS R©E in belangrijke mate TGF-β1 bevat, maar daarnaast ook TGF-β2, BMP-2,
-3, -7, IGF-1 en wellicht ook VEGF. Of zich ook nog andere groeifactoren in COLLOSS R©E
bevinden is mogelijk, maar kon niet worden bevestigd met de gebruikte technieken. Dit
mengsel van osteoinductieve factoren werkt waarschijnlijk synergistisch eﬀect, hetgeen een
verklaring zou kunnen zijn voor de botvorming, zoals deze werd gevonden in dierexperi-
menteel onderzoek. De concentratie van groeifactoren in COLLOSS R©E in deze studie was
laag, in vergelijking tot overeenkomstige studies met recombinant vervaardigde BMPs.
3: Gedraagt COLLOSS R©E zich osteoinductief, wanneer het ectopisch wordt ge¨ımplanteerd
in een klein diermodel?
In hoofdstuk 4 werd COLLOSS R©E toegepast in een klein diermodel. Van titanium gaas
werden zowel schijf- als cilindervormige implantaten vervaardigd. De cilinders werden gevuld
en de schijfjes ge¨ımpregneerd met COLLOSS R©E. Deze gevulde implantaten en lege controle
implantaten werden subcutaan aangebracht in ratten. Na respectievelijk 2, 8 en 12 weken,
werden de implantaten gee¨xplanteerd en werden er coupes van gemaakt. Het histologische
beeld toonde een dun ﬁbreus kapsel rondom de titanium implantaten met een milde weef-
selreactie. De schijfvormige implantaten, wel en niet ge¨ımpregneerd met COLLOSS R©E,
toonden helemaal geen botvorming. Na 2 weken lieten de cilindervormige implantaten in
60% van de gevallen botvorming zien, met een gemiddelde van 0,3 mm2 in oppervlakte.
Na 8 weken was dit 50% en 0,7 mm2 en na 12 weken 100% en 1,0 mm2. De lege cilinders
lieten geen botvorming zien. Geconcludeerd kan worden dat COLLOSS R©E, ingebracht in
een titanium cilinder, osteoinductieve eigenschappen bezit.
4: Wat is het eﬀect van een oplosbaar drager materiaal op de osteoinductiviteit van
COLLOSS R©E?
In hoofdstuk 5, werd gemineraliseerd collageen gebruikt als mogelijk dragermateriaal voor
COLLOSS R©E, in eenzelfde subcutaan rat model als beschreven in hoofdstuk 4. De col-
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lageen kokers werden gevuld met 40 mg COLLOSS R©E, of met een mengsel van 40 mg
COLLOSS R©E en beta-tricalcium fosfaat (β-TCP) korrels, of bleven leeg als controle. Van
alle 3 de groepen werden steeds 6 implantaten subcutaan ingebracht bij 18 ratten. Gedurende
de tijd dat de implantaten in situ waren, kon er een ontstekingsreactie worden waargenomen
in de huid boven het ge¨ımplanteerde gebied. Deze ontstekingsreactie kon na 12 weken his-
tologisch worden bevestigd. De coupes toonden eveneens dat er geen botvorming had
plaatsgevonden, de β-TCP korrels en het gemineraliseerde collageen waren duidelijk te on-
derscheiden. Deze bevinding staat haaks op de botvorming zoals werd gevonden in hoofd-
stuk 4, waarin een gelijksoortig diermodel werd gebruikt, maar dan met titanium cilinders in
plaats van collageen kokers. Hieruit kan worden geconcludeerd dat de osteoinductiviteit van
COLLOSS R©E kan worden belemmerd wanneer het dragermateriaal aanleiding geeft tot een
ontstekingsreactie. Aanvullende studies zijn nodig om puur het eﬀect van de toevoeging
van β-TCP korrels aan COLLOSS R©E te onderzoeken.
5: Kan COLLOSS R©E worden toegepast in benige defecten in een groot diermodel om de
botvorming te stimuleren?
De studie in hoofdstuk 6 was opgezet om de eigenschappen van COLLOSS R©E te on-
derzoeken in een benige omgeving in een groot proefdier. In 32 geiten werden circulaire
defecten met een diameter van 17 mm bilateraal in de kaakhoeken gemaakt. De defecten
werden opgevuld met COLLOSS R©E, β-TCP, een mengsel van COLLOSS R©E e´n β-TCP, of
werden leeg gelaten als controle. Na 9 weken werden de implantaten onderzocht door middel
van micro-CT en histomorphometrie. De lege defecten bevatten het hoogste percentage
aan gevormd botweefsel, namelijk 62%. De defecten gevuld met β-TCP resulteerden in
38% botvorming, het mengsel van de 2 materialen gaf aanleiding tot 36% bot en de met
COLLOSS R©E alleen gevulde defecten toonden 55% botvorming. Deze resultaten geven aan
dat het verwachtte eﬀect van de toevoeging van osteoconductieve β-TCP korrels uitbleef en
dat de korrels de botvorming zelfs leken te belemmeren. De toevoeging van COLLOSS R©E
leidde wel tot de vorming van eilandjes van bot in het midden van het defect, welke niet
waren verbonden met de randen van het defect. Deze botvorming in het centrum van het
defect werd niet waargenomen in defecten waaraan ge´e´n COLLOSS R©E was toegevoegd. Het
feit dat de lege defecten het hoogste percentage nieuw bot bevatten is onverwacht, maar
deze botvorming ontstond wel steeds vanuit de randen van het defect. De waargenomen
eilandjes bot in het midden van het defect wijzen opnieuw op de osteoinductiviteit van
COLLOSS R©E.
8.2 Conclusies
Vanwege de bezwaren die kleven aan het gebruik van autologe bottransplantaten en syn-
thetische botvervangende materialen, lijkt de techniek van tissue engineering voor de recon-
structieve chirurgie van het aangezichtsskelet veelbelovend. Dit proefschrift heeft proberen
aan te tonen dat de toepassing van COLLOSS R©E hieraan zou kunnen bijdragen. Door
middel van in vivo experimenten is de osteoinductiviteit van COLLOSS R©E bewezen. Deze
eigenschap is te danken aan de groeifactoren TGF-β1, TGF-β2, BMP-2, -3, -7, IGF-1 en
wellicht ook VEGF en de mogelijke interacties tussen deze verschillende groeifactoren. Zoals
ELISA, massaspectometrie en western blotting technieken uitwezen, is TGF-β1 de grootste
component in COLLOSS R©E. Het is goed mogelijk dat er nog meer groeifactoren dan de
hierboven genoemde aanwezig zijn in COLLOSS R©E, maar deze werden niet gevonden met
de gebruikte identiﬁcatie technieken.
107
Het klinische bewijs voor de osteoinductieve eigenschappen van COLLOSS R©E werd geleverd
door COLLOSS R©E in een ectopische omgeving te implanteren en aan te tonen dat zich na
een zekere periode botweefsel had gevormd. In het eerste in vivo experiment werd een
titanium drager gebruikt, voor klinische toepassing zou een oplosbare drager de voorkeur
verdienen. Daarom werd in een tweede, vergelijkbaar in vivo experiment een degradeerbare
drager gebruikt, vervaardigd van gemineraliseerd collageen. De osteoinductieve eigenschap-
pen van COLLOSS R©E bleken hierdoor echter belemmerd. Waarschijnlijk werd dit veroor-
zaakt door een ontstekingsreactie die werd opgewekt door de collagene drager. De tweede
hypothese in dit experiment, namelijk de verwachting dat de toevoeging van een osteo-
conductieve matrix in de vorm van β-TCP korrels de hoeveelheid gevormd bot zou doen
toenemen, werd niet bevestigd. Dit geldt ook voor de derde hypothese, dat een grotere
hoeveelheid COLLOSS R©E niet leidde tot meer botvorming.
Na bevestiging van de osteoinductieve capaciteit in een subcutane omgeving, werd vervol-
gens een derde in vivo experiment uitgevoerd, waarbij COLLOSS R©E in een benig defect
werd toegepast. De histologische resultaten toonden botvorming in het centrum van het
benige defect, niet verbonden aan de defect randen. Deze waarneming bevestigde het os-
teoinductieve gedrag van COLLOSS R©E. In dit experiment bleek ook de toevoeging van
een osteoconductieve matrix (β-TCP korrels) geen positief eﬀect te hebben op de botvor-
ming. Concluderend kan worden gesteld dat COLLOSS R©E voldoende potentie bezit om
de osteogenese te stimuleren, maar dat het gekozen degradeerbare dragermateriaal en de
osteoconductieve matrix niet voldeden aan de verwachtingen.
8.3 Toekomstperspectief
De belangrijkste component van COLLOSS R©E blijkt de groeifactor TGF-β1 te zijn. Het
is bekend dat TGF-β1 vooral verantwoordelijk is voor het mitogene eﬀect op osteoblasten.
De interactie tussen de verschillende groeifactoren die aanwezig zijn in COLLOSS R©E en
TGF-β1, is nog niet volledig opgehelderd. Deze interactie kan van groter belang zijn dan
nu bekend is. Toekomstig onderzoek zou deze interactie, alsmede mogelijke synergistische
eﬀecten, aan het licht kunnen brengen. Andere identiﬁcatie technieken dan ELISA, mas-
saspectometrie en western blotting zouden gebruikt kunnen worden om mogelijk andere
aanwezige groeifactoren te identiﬁceren in COLLOSS R©E.
De in vivo experimenten, zowel in kleine als grote proefdiermodellen, bewezen de osteoinduc-
tiviteit van COLLOSS R©E. Het eﬀect van de dosering van COLLOSS R©E op de uiteindelijk
gevormde hoeveelheid bot is echter nog steeds onbekend. Een titratie studie was geen on-
derdeel van dit proefschrift, maar zou in de toekomst kunnen worden uitgevoerd om een
mogelijk verband te kunnen aantonen.
Wanneer COLLOSS R©E werd aangebracht in een degradeerbare drager, bleek het osteoin-
ductieve gedrag te worden belemmerd door een optredende ontstekingsreactie. Of deze
belemmering alleen aan het gekozen collageen materiaal kon worden toegeschreven is niet
volledig duidelijk. Een belangrijk nadeel van de gekozen studieopzet was het feit dat er
3 parameters in e´e´n keer werden veranderd, namelijk het gekozen drager materiaal, de
hoeveelheid COLLOSS R©E en de toevoeging van een osteoconductieve matrix. Onderzoek,
waarbij slechts e´e´n parameter per keer gewijzigd wordt, zou de oorzaak voor deze belem-
mering deﬁnitief moeten uitwijzen.
Uit de resultaten van het onderzoek blijkt dat het gekozen degradeerbare drager materiaal
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niet geschikt was. Een geschikte drager voor COLLOSS R©E zou moeten voorkomen dat
COLLOSS R©E voortijdig uit het defect lekt, zodat er op de gewenste plaats stimulatie en
diﬀerentiatie van bot voorloper cellen plaats kan vinden. Daarnaast zou de drager moeten
degraderen in hetzelfde tempo als waarin nieuwe botvorming plaats vindt, om belemmering
van het bothelingsproces te voorkomen. Toekomstig onderzoek naar een geschikt drager-
materiaal bepaalt het succes van de klinische toepassing van COLLOSS R©E.
Ee´n van de gestelde hypotheses was de verwachting dat het toevoegen van een osteoconduc-
tieve matrix aan COLLOSS R©E, het proces van botvorming zou bevorderen. De resultaten
in dit proefschrift, echter, tonen aan dat er geen positief eﬀect op de botvorming werd
waargenomen. De gekozen mengverhouding van COLLOSS R©E en β-TCP zou hierin een
rol kunnen spelen. Toekomstige studies zouden erop gericht moeten zijn om een optimale
mengverhouding te bepalen. Daarnaast bleken de 2 afzonderlijke materialen moeilijk ver-
mengbaar met elkaar. In een vervolgstudie zou gekeken kunnen worden naar mogelijkheden
om de β-TCP korrels van een laagje COLLOSS R©E te voorzien.
De studie waarin COLLOSS R©E werd onderzocht in een benig defect in geiten, leverde
bewijs voor osteoinductieve eigenschappen van het materiaal. Daarnaast werd ook een
forse toeneming van de periostale botvorming waargenomen. Deze hoeveelheid bot kon
in de gekozen studieopzet echter niet worden gekwantiﬁceerd daar het verwijderen van de
geplaatste titanium markers deze metingen in de weg stonden. In toekomstig onderzoek
zou het interessant zijn om deze periostale botvorming juist wel te kwantiﬁceren. Dit eﬀect
van COLLOSS R©E in humane situaties kan van betekenis zijn, wanneer het wordt toegepast
in botdefecten waarbij het periost nog in tact is.
Samenvattend kan gesteld worden dat er nog zeker ruimte is voor nader onderzoek naar de
toepasbaarheid van COLLOSS R©E. Het is een natuurlijk product en geeft geen aanleiding
tot het ontstaan van ‘transmissible spongiform encephalopathy’ (TSE). Daarnaast is het
een veel goedkoper product dan de recombinant vervaardigde groeifactoren en bevat het
ook een mengsel van factoren met mogelijk synergistische eigenschappen. Het gebruik van
een dergelijk mengsel heeft als voordeel dat door de mogelijke interacties, zoals die ook in
de natuurlijke cascade van botvorming plaatsvinden, een veel eﬀectiever materiaal gecree¨erd
wordt in vergelijking tot het gebruik van e´e´n enkele recombinant vervaardigde groeifactor.
Toekomstig onderzoek zou zich moeten richten, in opeenvolgende stappen, op het gebruik
van de juiste hoeveelheden COLLOSS R©E, mengverhoudingen, dragermateriaal en matrix,
met als uiteindelijk doel het cree¨ren van een materiaal dat klinisch toepasbaar is.
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Hooggeleerde promotor Stoelinga, mijn uiteindelijke keuze voor het specialisme Mondziek-
ten, Kaak- en Aangezichtschirurgie heeft zijn oorsprong in uw aanstekelijke enthousiasme
welke ik voor het eerst mocht ervaren als student Tandheelkunde. Na mijn uitwisselingsstage
in Zuid-Afrika kon ik op uw afdeling komen werken als ‘onderwijscoo¨rdinator’ en om mij de
dento-alveolaire chirurgie eigen te maken. U stimuleerde mij voorzichtig richting ‘weten-
schappelijk onderzoek’ met uiteindelijk een promotietraject en dit proefschrift als resultaat.
Zonder uw inspirerende en motiverende ‘druk’ was dat nooit gelukt. Aanvankelijk verliepen
de e-mail contacten ‘via Ria’ heen-en-weer. Inmiddels heeft u mij bijna ingehaald met uw
‘digi-skills’ ! Na uw emeritaat zetten wij onze besprekingen voort in Driel waar de koﬃe
altijd klaar stond. Geduldig werd mijn ‘turbo-Nederlands-Engels’ steeds weer gecorrigeerd.
Na deze avonden, hoe onmogelijk voor mij soms de combinatie van studie, onderzoek en
werk ook voelde, kon ik weer met goede moed vooruit. Ik ben dankbaar dat u mijn promotor
heeft willen zijn. Dat ik nu mag promoveren op uw 70ste verjaardag ervaar ik als een grote
eer.
Hooggeleerde promotor Jansen, bedankt voor de stimulerende en zeer eﬃcie¨nte begeleiding.
Het maakte niet uit op welk tijdstip ik een concept-artikel stuurde, in no-time had ik uw
grondige revisie binnen. Op belangrijke kruispunten op mijn onderzoekspad kwam u steeds
met ne´t het juiste commentaar en dat heb ik zeer gewaardeerd.
Dr. Walboomers, beste Frank, als mijn copromotor wil ik je bedanken voor je prettige en
intensieve begeleiding. Met je eeuwige geduld en onvoorwaardelijke hulp, fungeerde jij als
mijn rode draad door dit hele onderzoekstraject. Ik kon met elke vraag bij je terecht, waar
ik ook maar vastliep. Je relativerende woorden hebben mij regelmatig over een ‘dipje’ heen
geholpen, veel dank daarvoor.
Prof. Merkx, Prof. Wismeijer, dr. Van Kuppevelt: bedankt voor het beoordelen van het
manuscript en het voeren van de oppositie. Thijs in het bijzonder, dank je wel voor je hulp
en je betrokkenheid. Jouw woorden in mijn exemplaar van jouw boekje waren inderdaad de
eerste aanzet!
Vincent Cuijpers, dank voor je steeds weer snelle antwoorden op al mijn vragen. Natasja
van Dijk, dank voor je uitleg en hulp bij de verwerking van alle histologie in het Bioma-
terialen lab. Meike van de Zande, bedankt voor je grote bijdrage aan en je kritische
blik als coauteur op de in vitro studie. Alex Hanssen en Jeroen Mooren, dank voor de
prettige samenwerking in het CDL. De uurtjes aan de OK-tafel met jullie waren een erg leuk
onderdeel van mijn onderzoek. Jan Mulder, bedankt voor de statistische ondersteuning.
Dr. Meijer, beste Gert, bedankt voor je waardevolle bijdrage aan de totstandkoming van
hoofdstuk 2. Luc Verhamme, heel veel dank voor al je hulp bij het lay-out werk!
I would like to acknowledge Danfoss Bionics, Ossacur AG, for kindly contributing the
Colloss R©E and Ossoplast R© and especially Arne Briest for his stimulating input in this
study. I would also like to thank Ole Jensen and Kjeld Poulsen for preparation of the
data, as used in Chapter 3. I am greatly indebted to Prof. Michael Gelinsky, who provided
the mineralized collagen scaﬀolds, but above all for his critical comments on the results, as
described in Chapter 5.
Beste Rob Mooren, onder jouw leiding heb ik de eerste stappen in dierexperimenteel on-
derzoek gezet. Veel respect heb ik voor je precisie en toewijding. Dank voor de chirurgische
vaardigheden die je me hebt bijgebracht.
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Cogroep 96, heerlijk relativerend was het om met jullie de coschappen te mogen doorlopen.
De gezelligheid en lol overdag maakten dat ik me ’s avonds weer beter op mijn onderzoek
kon richten. Heb me heerlijk thuis gevoeld bij jullie. Altijd was er begrip voor ‘de tandarts’
die weer ergens moest werken. Lieve Luud, Roos en Biebs, dank jullie wel voor jullie
vriendschap. Ja Luud; MOOIE mensen zijn jullie! Ik ben erg blij dat ik met jullie zoveel
mooie momenten heb beleefd en dat jullie me door sommige moeilijke hebben weten heen
te slepen.
Familie Zilverschoon, lieve Richard, Emile, Anneke, Ria, Olga, Wilma, Nancy & Nancy,
Klaske en Joan. De donderdagen waren voor mij een feest! Naast al die andere hectische
dagen in mijn week vond ik in Duiven heerlijke aﬂeiding in jullie altijd gezellige nest. Het
enige lastige aan het geheel was het feit dat het werken met jullie me veel te goed beviel.
Ik vind het ontzettend mooi dat ik dit feest met jullie erbij mag vieren en ik hoop nog heel
lang contact met jullie te houden!
Dirk Mettes, mijn nestor! Dank voor je geruststellende woorden op zijn tijd. Ik hoop dat
ik nog lang met je mag samenwerken, aan welk project dan ook! Charlotte Mettes jr,
dank je wel voor je mooie illustraties. Dat we nog maar vele uurtjes samen in ‘Anneke’
belevenissen mogen blijven uitwisselen.
Lieve Martina, je belde altijd precie´s op het juiste moment. Samen op zondagmiddag even
’mopperen’ over onderzoek doen. Ik heb jouw aanwezigheid als een ﬁjne ruggesteun ervaren,
dank daarvoor! Heel veel succes met jouw laatste loodjes.
Lieve Willeke, stil op de achtergrond heb je steeds voor me klaargestaan. Dat heeft me
heel veel goed gedaan. Nu´ is het moment om je daarvoor te kunnen bedanken. Ik hoop dat
we elkaar nog heel lang van dichtbij zullen volgen.
Beste paranimfen, lieve Arieke en Sandra, mijn rotsen in de branding, ieder op je eigen
manier. Ik ben er trots op dat jullie als paranimfen aan mijn zijde willen staan. San, ik
ben erg dankbaar dat onze paden kruisten in HVW 122. Samen hebben we heerlijk kunnen
bakkeleien over ‘de dingen des levens’; ik hoop dat we dat nog vaak blijven doen! Lieve
Aar, ik heb erg uitgekeken naar deze dag, die ik graag met jou wil vieren. Een van de betere
zetten in mijn leven was om jou mee te vragen naar Zuid-Afrika. Veel respect heb ik voor
je eeuwige geduld, je onvoorwaardelijke vriendschap en je onbegrensde steun in moeilijke
tijden. Steeds weer was je mijn klankbord, in welke situatie ik ook verkeerde. Ongelooﬂijk
veel dank daarvoor! En je weet het he`: als we 80+ zijn, kijken we terug op al die mooie
dingen die we beleefd hebben en dat zijn er heel veel!
Vriendinnen en vrienden, dank voor de nodige en he´e´rlijke ontspanning tijdens de afgelopen
jaren. Dank ook voor het constante begrip voor mijn altijd volle agenda. De gaatjes erin
gaan vanaf nu alleen maar groter worden, dus no´g meer tijd voor leuke dingen!
Simon, Hanneke, Jasper en Yvonne, wat hadden we het toch weer lekker druk he`? Jullie
keken al lang niet meer op van al die honderdduizend dingen tegelijk. Misschien wel af en
toe jullie hoofd geschud, maar de interesse was er altijd! Inmiddels zijn er meerdere van die
dingen afgerond en ben ik blij dat ik vandaag met jullie de´ze mijlpaal mag vieren. Simon
en Jasper, bedankt voor jullie broederlijke ondersteuning van twee kanten!
Papa enMama, je opvoeding legt de basis voor de persoon die je nu bent. Doorzettingsver-
mogen is een belangrijke eigenschap die ik daaruit heb meegekregen en zonder deze was ik
niet tot hier gekomen.
Dank jullie wel voor alles.
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